,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,880,2,1,,26751802,4946,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
1,880,2,1,,26751802,4946,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
2,1030,2,1,,26751802,4946,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
3,1195,1,2,,48416484,4946,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
4,1332,1,1,,49698887,4946,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
5,1457,1,1,,26751802,4946,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
6,1458,1,1,,26751802,4946,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
7,1460,1,3,,26751802,4946,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
8,1463,1,1,,26751802,4946,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
9,1468,1,1,,26751802,4946,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
10,1469,1,1,,26751802,4946,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
11,1471,2,1,,26751802,4946,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
12,1477,1,1,,26751802,4946,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
13,1479,1,2,,26751802,4946,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
14,1490,2,1,,26751802,4946,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
15,1865,1,1,,26751802,4946,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
16,1949,1,3,,49904222,4946,Inactive,,,,,"High Throughput Screen of 100,000 compound library to Identify Inhibitors of Mycobacterium tuberculosis H37Rv",Confirmatory,,
17,2062,1,2,,85209402,4946,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
18,2101,1,1,,26751802,4946,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
19,2107,1,1,,26751802,4946,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
20,2112,1,1,,26751802,4946,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
21,2240,1,1,,85787395,4946,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
22,2241,1,1,,85787395,4946,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
23,2275,1,1,,85787395,4946,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
24,2313,1,1,,85787395,4946,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
25,2316,1,1,,85787395,4946,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
26,2322,1,1,,85787395,4946,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
27,2330,1,1,,85787395,4946,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
28,2517,2,1,,26751802,4946,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
29,2549,1,1,,26751802,4946,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
30,2660,1,1,,90341556,4946,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
31,2666,1,1,,90341556,4946,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
32,2667,1,1,,90341556,4946,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
33,2668,1,1,,90341556,4946,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
34,3616,7,1,,103164951,4946,Active,,,0.05,Ki,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,Confirmatory,2539480.0,
35,4036,8,5,,103164951,4946,Active,112812.0,24473.0,0.113,Ki,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Confirmatory,8230102.0,
36,4253,4,7,,103164951,4946,Unspecified,,,10.0,Ki,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,Confirmatory,9435911.0,
37,4330,7,1,,103164951,4946,Active,,,0.09,Ki,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Confirmatory,2539480.0,
38,7625,3,4,,103164951,4946,Unspecified,,,,,In vitro metabolic potential in mouse liver microsomes,Other,12668020.0,
39,7779,3,3,,103164951,4946,Unspecified,,,,,Oral bioavailability in human,Other,11784135.0,
40,7783,3,4,,103164951,4946,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
41,7804,3,4,,103164951,4946,Unspecified,,,,,In vitro metabolic potential in human liver microsomes,Other,12668020.0,
42,7812,3,3,,103164951,4946,Unspecified,,,,,In vitro rate of absorption observed as Caco-2 permeability in humans,Other,11784135.0,
43,7974,3,4,,103164951,4946,Unspecified,,,,,Metabolic stability observed at 30 min after administration in human liver microsomes,Other,11784135.0,
44,8002,5,2,,103164951,4946,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
45,9532,3,4,,103164951,4946,Unspecified,,,,,In vitro metabolic potential in dog liver microsomes,Other,12668020.0,
46,13443,3,4,,103164951,4946,Unspecified,,,,,In vitro metabolic potential in rat liver microsomes,Other,12668020.0,
47,16351,3,3,,103164951,4946,Unspecified,,,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,Other,2892933.0,
48,19006,4,3,,103164951,4946,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
49,19419,3,4,,103164951,4946,Unspecified,,,,,Partition coefficient (logD7.4),Other,9544199.0,
50,19424,3,4,,103164951,4946,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
51,19560,3,4,,103164951,4946,Unspecified,,,,,Hill coefficient of the compound,Other,8230102.0,
52,20050,3,3,,103164951,4946,Unspecified,,,,,Human absorption A (%),Other,9544199.0,
53,20062,3,3,,103164951,4946,Unspecified,,,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water.,Other,2878080.0,
54,20866,3,4,,103164951,4946,Unspecified,,,,,Compound was determined for partition coefficient,Other,6148422.0,
55,21233,3,3,,103164951,4946,Unspecified,,,,,Partition coefficient of compound in to biological membranes,Other,2002467.0,
56,21234,3,4,,103164951,4946,Unspecified,,,,,Partition coefficient of compound in to octanol/buffer,Other,2002467.0,
57,21271,7,1,,103164951,4946,Unspecified,,,,,Mean apparent permeability through fuzzy rat skin,Other,2892933.0,
58,21277,7,1,,103164951,4946,Unspecified,,,,,Permeability through isolated albino rabbit cornea,Other,2892933.0,
59,21849,7,1,,103164951,4946,Unspecified,,,,,In vitro clearance in dog in 1000000 cells,Other,10602692.0,
60,21851,7,1,,103164951,4946,Unspecified,,,,,In vitro clearance in human in 1000000 cells,Other,10602692.0,
61,21852,7,1,,103164951,4946,Unspecified,,,,,In vitro clearance in rat in 1000000 cells,Other,10602692.0,
62,21854,6,2,,103164951,4946,Unspecified,,,,,In vivo clearance in dog.,Other,10602692.0,
63,21857,6,2,,103164951,4946,Unspecified,,,,,In vivo clearance in human.,Other,10602692.0,
64,21859,6,2,,103164951,4946,Unspecified,,,,,In vivo clearance in rat.,Other,10602692.0,
65,22764,6,2,,103164951,4946,Unspecified,,,,,T1/2 in canine blood,Other,6146718.0,
66,23271,4,4,,103164951,4946,Unspecified,,,,,Partition coefficient (logD7.4),Other,2362268.0,
67,24180,3,3,,103164951,4946,Unspecified,,,,,Permeability coefficient reported; (Expressed as Permeability coefficient x 10 e 4 cm/s),Other,8941388.0,
68,25356,3,3,,103164951,4946,Unspecified,,,,,Compound was evaluated for pKa value by potentiometric titration,Other,6148422.0,
69,26250,3,4,,103164951,4946,Unspecified,,,,,Compound was evaluated for distribution coefficient,Other,2878080.0,
70,26292,3,4,,103164951,4946,Unspecified,,,,,Partition coefficient (logD7.4),Other,6115057.0,
71,26362,4,3,,103164951,4946,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
72,26765,3,3,,103164951,4946,Unspecified,,,,,Partition coefficient (logP),Other,2878080.0,
73,27167,3,4,,103164951,4946,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
74,28233,3,3,,103164951,4946,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
75,28234,3,4,,103164951,4946,Unspecified,,,,,% absorbed in human GI-tract,Other,11300874.0,
76,28235,3,3,,103164951,4946,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
77,28236,3,3,,103164951,4946,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
78,28679,3,4,,103164951,4946,Unspecified,,,,,Partition coefficient (logD6.8),Other,11300874.0,
79,28681,3,4,,103164951,4946,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
80,28921,3,3,,103164951,4946,Unspecified,,,,,Partition coefficient (logP) (hexadecane),Other,11300874.0,
81,28923,3,4,,103164951,4946,Unspecified,,,,,Effective permeability measured with Caco-2 cells,Other,11300874.0,
82,28924,3,3,,103164951,4946,Unspecified,,,,,Effective permeability (Pe) across a hexadecane membrane (pH 6.8),Other,11300874.0,
83,28925,3,3,,103164951,4946,Unspecified,,,,,Highest effective permeability across hexadecane membrane (pH 4-8),Other,11300874.0,
84,28926,3,3,,103164951,4946,Unspecified,,,,,Effective permeability corrected for ionization,Other,11300874.0,
85,28928,3,3,,103164951,4946,Unspecified,,,,,Intrinsic permeability of the compound,Other,11300874.0,
86,29139,4,3,,103164951,4946,Unspecified,,,,,"Calculated dissociation constant (pKa, calculated with ACD/pKa)",Other,12477351.0,
87,29337,3,3,,103164951,4946,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
88,29359,3,3,,103164951,4946,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
89,29423,3,4,,103164951,4946,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
90,29812,3,3,,103164951,4946,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
91,29845,3,4,,103164951,4946,Unspecified,,,,,Estimation of fraction absorbed (Fa) in the human intestine using biosensor technology.,Other,10841786.0,
92,29925,5,2,,103164951,4946,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
93,33116,3,8,,103164951,4946,Unspecified,,,,,Relative adrenoceptor blocking activity (DR10) was recorded for the antagonism of Phenylephrine-induced vasopressor responses in Alpha adrenergic receptor blockade the anesthetized dog,Other,6124636.0,
94,33124,5,4,,103164951,4946,Unspecified,,,100.0,Kd,Evaluated for norepinephrine as agonist.,Confirmatory,6124636.0,
95,37016,7,1,,103164951,4946,Unspecified,,,100.0,IC50,Inhibition of alpha-1 adrenergic receptor isolated from rat ventricle homogenates,Confirmatory,9572886.0,
96,39943,9,2,,103164951,4946,Active,,,0.0017399999999999998,Kd,In vitro inhibitory activity against beta-1 adrenergic receptor measured by inhibition of positive chronotropic effect of isoproterenolin in isolated guinea pig atria,Confirmatory,2872332.0,
97,39950,8,2,,103164951,4946,Active,,,0.002,Kd,Ability to block Beta-1 adrenergic receptor in guinea pig right atria preparation,Confirmatory,6130154.0,
98,40395,5,3,,103164951,4946,Active,,,0.0024,Kd,Beta-1 adrenergic receptor-Antagonism in isolated rat heart ventricle. ( for R-enantiomer),Confirmatory,9572886.0,
99,40396,5,3,,103164951,4946,Active,,,2.63027,Kd,Beta-1 adrenergic receptor-Antagonism in isolated rat heart ventricle. ( for S-enantiomer),Confirmatory,9572886.0,
100,40404,3,9,,103164951,4946,Unspecified,114754.0,24925.0,,,Apparent dissociation constant towards beta-1 adrenergic receptor in rat heart membranes using (2-6)x10E-9M of [3AH]-DHA in the presence or absence of 10e-5 M (+/-) propranolol.,Other,3031293.0,
101,40420,6,3,,103164951,4946,Active,,,0.004370000000000001,Kd,Antagonist activity was determined against beta-1 adrenergic receptor in spontaneously beating rat atria,Confirmatory,2884312.0,
102,40527,5,3,,103164951,4946,Active,,,0.004370000000000001,Kd,Cardioselectivity for the beta-1 adrenergic receptor was determined against isoprenaline (antagonism) in isolated rat atria,Confirmatory,2884312.0,
103,40537,3,7,,103164951,4946,Active,,,,,Selectivity for beta-1 adrenergic receptor,Other,2903243.0,
104,40703,10,5,,103164951,4946,Active,1703760.0,403910.0,0.017,IC50,Tested for Beta-2 adrenergic receptor selectivity in canine lung tissue in anesthetized dogs,Confirmatory,1976812.0,
105,40704,6,7,,103164951,4946,Unspecified,1703760.0,403910.0,,,The compound was tested for beta-2 adrenergic receptor blocking activity in dogs,Other,3001305.0,
106,40707,3,10,,103164951,4946,Unspecified,1703760.0,403910.0,,,Apparent pA2 value for isoproterenol-induced vasodilation (beta2) evaluated against beta-2 adrenergic receptor in anesthetized dogs,Other,2861287.0,
107,40713,8,5,,103164951,4946,Active,81914759.0,100722663.0,0.028839999999999998,IC50,Inhibitory activity against beta-2 adrenergic receptor in guinea pig tracheal strip is determined,Confirmatory,8230093.0,
108,40716,7,1,,103164951,4946,Active,81914759.0,100722663.0,,,In vitro affinity constant against beta-2 adrenergic receptor from guinea pig trachea,Other,6138434.0,
109,40718,6,6,,103164951,4946,Active,81914759.0,100722663.0,0.04365,Kd,Antagonist activity of compound against Beta-2 adrenergic receptor in isolated guinea pig trachea,Confirmatory,6120237.0,
110,40845,5,6,,103164951,4946,Unspecified,81914759.0,100722663.0,,,Blocking activity against Beta-2 adrenergic receptor in guinea pig tracheal strips,Other,6120233.0,
111,40860,3,10,,103164951,4946,Unspecified,81914759.0,100722663.0,,,Ratio of EC50 of test to control evaluated in guinea pig tracheal strips (beta2),Other,6120233.0,
112,40867,8,5,,103164951,4946,Active,81914759.0,100722663.0,0.00339,Kd,Beta-2 adrenergic receptor blocking activity in trachea of guinea pig.,Confirmatory,6148422.0,
113,40869,9,5,,103164951,4946,Active,81914759.0,100722663.0,0.00302,Kd,In vitro beta-2 adrenergic receptor activity was determined by measuring inhibition of the isoproterenol induced relaxation in isolated guinea pig tracheal chains contracted with PGF2-alpha,Confirmatory,6134834.0,
114,40870,9,5,,103164951,4946,Active,81914759.0,100722663.0,0.000977,Kd,In vitro inhibitory activity against beta-2 adrenergic receptor was measured by the inhibition of isoproterenol-induced relaxation of PGF2-alpha contracted guinea pig trachea,Confirmatory,2872332.0,
115,40873,9,5,,103164951,4946,Active,81914759.0,100722663.0,0.00339,Kd,In vitro inhibitory activity against beta-2 adrenergic receptor determined as pA2 in guinea pig trachea,Confirmatory,2861288.0,
116,40877,8,5,,103164951,4946,Active,81914759.0,100722663.0,0.00126,Kd,Ability to block Beta-2 adrenergic receptor in guinea pig trachea preparation,Confirmatory,6130154.0,
117,41136,9,2,,103164951,4946,Active,,,0.012,IC50,"Tested for Beta Adrenergic receptor binding inhibition from canine ventricular tissue, using [3H]dihydroalprenolol as the radioligand in anesthetized dogs",Confirmatory,1976812.0,
118,41150,3,5,,103164951,4946,Unspecified,,,,,Beta adrenergic receptor antagonist potency relative to propranolol.,Other,6115057.0,
119,41151,3,7,,103164951,4946,Unspecified,,,,,Apparent pA2 value for blockade of isoproterenol-induced increase in heart rate evaluated against beta adrenergic receptor in anesthetized dogs,Other,2861287.0,
120,41152,9,2,,103164951,4946,Active,,,0.004,IC50,Concentration effective against displacing [3H]dihydroalprenolol from beta adrenergic receptor from canine ventricular tissue,Confirmatory,3560162.0,
121,41154,7,2,,103164951,4946,Active,,,0.002,Kd,In Vitro inhibition of the beta adrenergic receptor in guinea pig atria,Confirmatory,6146718.0,
122,41156,7,3,,103164951,4946,Active,,,0.00126,Kd,In vitro blocking of beta adrenergic receptor in guinea pig trachea,Confirmatory,6146718.0,
123,41299,4,1,,103164951,4946,Active,,,,,Antagonist activity for blockade of beta adrenergic receptor of isolated guinea pig atrial pairs,Other,2878080.0,
124,41305,7,2,,103164951,4946,Active,,,0.0036299999999999995,Kd,Beta adrenergic receptor blocking activity measured by the chronotropic effect was determined 1 hr after pretreatment of the right atria in guinea pig,Confirmatory,6147415.0,
125,41306,7,2,,103164951,4946,Active,,,0.0024,Kd,Beta adrenergic receptor blocking activity measured by the inotropic effect was determined 1 hr after pretreament of the right atria in guinea pig,Confirmatory,6147415.0,
126,41347,7,7,,103164951,4946,Unspecified,114768.0,24176.0,,,Antagonistic activity against beta-2 adrenergic receptor as inhibition of vasopressor response in rats,Other,2866246.0,
127,41348,7,4,,103164951,4946,Unspecified,,,,,Beta-2 adrenergic receptor blockade measured as inhibition of depressor response caused by isoprenaline in anesthetized rats when administered intravenously,Other,6138434.0,
128,41476,8,3,,103164951,4946,Inconclusive,,,,,The compound was tested for the concentration to inhibit 50% of Beta-2 adrenergic receptor isolated from rat lung homogenates; ND=not determined,Other,9572886.0,
129,41477,3,9,,103164951,4946,Unspecified,114768.0,24176.0,,,Apparent dissociation constant towards beta-2 adrenergic receptor in rat lung membranes using (2-6)x10E-9M of [3AH]-DHA in the presence or absence of 10e-5 M (+/-) propranolol.,Other,3031293.0,
130,41482,5,3,,103164951,4946,Active,,,0.0017800000000000001,Kd,Compound was evaluated for competitive antagonism of beta-2 adrenergic receptor in rat uterus measured as pA2 (-log KB),Confirmatory,6330358.0,
131,41488,3,7,,103164951,4946,Active,,,,,Selectivity for beta-2 adrenergic receptor,Other,2903243.0,
132,41607,9,2,,103164951,4946,Active,,,0.03,IC50,Inhibitory concentration required for displacement of Beta adrenergic receptor specific ligand [3H]dihydroalprenolol from rat brain cerebral cortical membranes,Confirmatory,6124637.0,
133,41610,7,1,,103164951,4946,Active,,,0.003,IC50,The compound was tested for the concentration to inhibit 50% of Beta adrenergic receptor isolated from rat ventricle homogenates,Confirmatory,9572886.0,
134,41752,9,3,,103164951,4946,Active,114754.0,24925.0,1.6,Ki,Inhibition constant from beta adrenergic receptor binding assay,Confirmatory,2909730.0,
135,41752,9,3,,103164951,4946,Active,114768.0,24176.0,1.6,Ki,Inhibition constant from beta adrenergic receptor binding assay,Confirmatory,2909730.0,
136,41752,9,3,,103164951,4946,Active,543882.0,25645.0,1.6,Ki,Inhibition constant from beta adrenergic receptor binding assay,Confirmatory,2909730.0,
137,41754,7,1,,103164951,4946,Active,,,0.0024,Ki,Inhibitory activity against beta adrenergic receptor of rat frontal cortex homogenate using (1.0 nM) [3H]- dihydroalprenolol,Confirmatory,2539480.0,
138,41760,3,8,,103164951,4946,Unspecified,,,,,In vitro inhibitory specificity for Beta adrenergic receptor was evaluated,Other,9572886.0,
139,41890,3,6,,103164951,4946,Active,,,,,Tested for intrinsic sympathomimetic activity (ISA); Pure antagonist,Other,2903243.0,
140,41895,3,7,,103164951,4946,Unspecified,,,,,Beta-blocking activity was measured by applying the stepwise linear discriminate analysis; Active,Other,,
141,41903,3,7,,103164951,4946,Unspecified,,,,,"Beta adrenoceptor blocking potency was estimated by inhibition of 50% of the tachycardia produced by a submaximal dose of the isoproterenol (0.2ug/kg, intravenously)",Other,6118435.0,
142,42020,9,2,,103164951,4946,Active,,,0.0024,Kd,In vitro inhibitory activity against beta-1 adrenergic receptor determined as pA2 in guinea pig atria,Confirmatory,2861288.0,
143,42024,3,7,,103164951,4946,Unspecified,,,,,Apparent pA2 value for myocardial contractile force (beta-1) evaluated against beta-1 adrenergic receptor in anesthetized dogs,Other,2861287.0,
144,42031,9,2,,103164951,4946,Active,,,0.018000000000000002,IC50,Tested for Beta-1 adrenergic receptor selectivity in canine cardiac tissue in anesthetized dogs,Confirmatory,1976812.0,
145,42032,6,4,,103164951,4946,Unspecified,,,,,Compound was tested for beta-1 adrenergic receptor blocking activity in dogs,Other,3001305.0,
146,42036,8,2,,103164951,4946,Active,,,0.03467,IC50,Inhibitory activity against beta-1 adrenergic receptor in guinea pig atria is determined,Confirmatory,8230093.0,
147,42039,7,1,,103164951,4946,Active,,,,,In vitro affinity constant against beta-1 adrenergic receptor from guinea pig artia,Other,6138434.0,
148,42040,6,2,,103164951,4946,Active,,,0.008709999999999999,Kd,Antagonist activity of compound against Beta-1 adrenergic receptor in isolated guinea pig left atria,Confirmatory,6120237.0,
149,42051,5,4,,103164951,4946,Unspecified,,,,,Blocking activity against Beta-1 adrenergic receptor in spontaneously beating guinea pig atrial preparations,Other,6120233.0,
150,42197,3,8,,103164951,4946,Unspecified,,,,,Ratio of EC50 of test to control evaluated in guinea pig atria (beta-1),Other,6120233.0,
151,42208,8,3,,103164951,4946,Active,,,0.00251,Kd,Beta-1 adrenergic receptor activation measured by isoprenaline-induced positive inotropic effect in guinea pig left atrium,Confirmatory,2903245.0,
152,42209,8,2,,103164951,4946,Active,,,0.0024,Kd,Beta-1 adrenergic receptor blocking activity in atria of guinea pig.,Confirmatory,6148422.0,
153,42210,6,2,,103164951,4946,Active,,,0.01259,Kd,Cardioselectivity for the beta-1 adrenergic receptor was determined against isoprenaline (antagonism) in isolated guinea pig trachea,Confirmatory,2884312.0,
154,42211,6,2,,103164951,4946,Active,,,0.00309,Kd,Compound was evaluated for competitive antagonism of beta-1 adrenergic receptor in guinea pig atria measured as pA2 (-log KB),Confirmatory,6330358.0,
155,42218,9,3,,103164951,4946,Active,,,0.0017399999999999998,Kd,In vitro beta-1 adrenergic receptor activity was determined via inhibition of the positive chronotropic actions of isoproterenol in isolated guinea pig atrial preparations,Confirmatory,6134834.0,
156,45741,3,4,,103164951,4946,Unspecified,,,,,Collateral sensitivity of CHRC5 cells to local anesthetics/steroids as log of ratio of molar concentration of drug inducing 50% growth inhibition in CHO AUXB1 cells to that of CHRC5 cells,Other,2362268.0,
157,47781,3,3,,103164951,4946,Unspecified,,,,,Duration of hypotensive activity in cat following i.v. administration of 1 mg/kg,Other,15125935.0,
158,47782,3,3,,103164951,4946,Unspecified,,,,,Duration of hypotensive activity in cat following i.v. administration of 5 mg/kg,Other,15125935.0,
159,47944,6,3,,103164951,4946,Unspecified,,,,,Beta-adrenergic blocking potency to inhibit tachycardia in anesthetized cats,Other,6131134.0,
160,47972,6,4,,103164951,4946,Unspecified,,,,,In vivo beta adrenergic blocking potency was determined by inhibition of tachycardia produced by isoproterenol (0.2 mg/kg iv) in cat preparation,Other,6128420.0,
161,47973,6,2,,103164951,4946,Unspecified,,,,,In vivo beta adrenoceptor blocking potency was determined by inhibition of tachycardia in cat,Other,6130155.0,
162,48143,3,4,,103164951,4946,Unspecified,,,,,Hypotensive activity in cat following i.v. administration of 1 mg/kg expressed as fall in blood pressure,Other,15125935.0,
163,48145,3,4,,103164951,4946,Unspecified,,,,,Hypotensive activity in cat following i.v. administration of 5 mg/kg expressed as fall in blood pressure,Other,15125935.0,
164,48147,3,4,,103164951,4946,Unspecified,,,,,Fall of blood pressure in anaesthetized cat at a dose of 1 mg/kg intravenously,Other,15149670.0,
165,48148,3,4,,103164951,4946,Unspecified,,,,,Fall of blood pressure in anaesthetized cat at a dose of 5 mg/kg intravenously,Other,15149670.0,
166,48346,7,3,,103164951,4946,Unspecified,,,,,Beta-1-adrenoceptor antagonsim of compound expressed as inhibition of isoprenaline-induced tachycardia in the ganglion-blocked anesthetized cat,Other,2892934.0,
167,48524,4,1,,103164951,4946,Unspecified,,,,,In vivo beta-adrenoceptor blocking potency in cat (expressed as total dose infused over a period of 30 minutes causing 50% inhibition of the tachycardia by iv administration),Other,6106716.0,
168,48526,4,5,,103164951,4946,Unspecified,,,,,"Beta-adrenoceptor blocking potency in cat, measured as the degree (percent) of blockade of the vasopressor response at the dose level",Other,6106716.0,
169,48535,3,8,,103164951,4946,Unspecified,,,,,In vivo beta adrenergic blocking potency was determined by inhibition of depressor response produced by isoproterenol (0.2 mg/kg iv) in cat preparation,Other,6128420.0,
170,48536,3,8,,103164951,4946,Unspecified,,,,,In vivo beta-adrenergic blocking potency to inhibit vasopressor response in anesthetized cats,Other,6131134.0,
171,48537,3,7,,103164951,4946,Unspecified,,,,,Percent inhibition of vasopressor response,Other,6118435.0,
172,48541,3,3,,103164951,4946,Unspecified,,,,,The compound was evaluated for inhibition of depressor response.,Other,6130155.0,
173,48727,3,4,,103164951,4946,Unspecified,,,,,Hypotensive activity in cat following i.v. administration of 1 mg/kg expressed as fall in blood pressure,Other,15125935.0,
174,48729,3,4,,103164951,4946,Unspecified,,,,,Hypotensive activity in cat following i.v. administration of 5 mg/kg expressed as fall in blood pressure,Other,15125935.0,
175,48734,3,3,,103164951,4946,Unspecified,,,,,Percent of maximum effect in anaesthetized cat at a dose of 1 mg/kg intravenously,Other,15149670.0,
176,48735,3,3,,103164951,4946,Unspecified,,,,,Percent of maximum effect in anaesthetized cat at a dose of 5 mg/kg intravenously,Other,15149670.0,
177,50194,5,3,,103164951,4946,Unspecified,,,,,Ability to lower arterial blood pressure in cat at 200 ug/kg; reversed,Other,6854584.0,
178,55922,3,3,,103164951,4946,Unspecified,,,,,Cardiac slowing index was measured for potency and efficacy,Other,6687480.0,
179,58409,4,3,,103164951,4946,Unspecified,,,,,Time taken for 80% recovery at a dose of 1.3 microg (3-h infusion period),Other,6146718.0,
180,58437,6,1,,103164951,4946,Unspecified,,,,,Change in heart rate at the above D50 dose in conscious dogs,Other,6687480.0,
181,58438,3,4,,103164951,4946,Unspecified,,,,,Percent decrease from initial heart rate (percent delta HR50/HR0 x 100) in dogs,Other,6687480.0,
182,58612,3,3,,103164951,4946,Unspecified,,,,,Concentration required to reverse ouabain induced arrhythmia in dogs,Other,7359531.0,
183,58613,3,3,,103164951,4946,Unspecified,,,,,Concentration required to decrease hindlimb perfusion pressure(55 mmHg) in anesthetized dogs after intra arterial administration.,Other,6115057.0,
184,58751,3,3,,103164951,4946,Unspecified,,,,,Relative activity (fraction of the most active compound 24) was determined,Other,6687480.0,
185,58778,4,3,,103164951,4946,Unspecified,,,,,Duration of ischemic arrhythmias in dogs determined in minutes.,Other,6147415.0,
186,58918,3,3,,103164951,4946,Unspecified,,,,,Vasodilator potency relative to propranolol.,Other,6115057.0,
187,58964,3,3,,103164951,4946,Unspecified,,,,,Duration of the reversal of ouabain induced arrhythmia was measured,Other,7359531.0,
188,59158,3,3,,103164951,4946,Unspecified,,,,,Heart rate of the dog was measured after drug administration to dogs,Other,7359531.0,
189,59159,3,3,,103164951,4946,Unspecified,,,,,Heart rate of the dog was measured after ouabain administration to dogs,Other,7359531.0,
190,59381,3,3,,103164951,4946,Unspecified,,,,,Myocardial depression in conscious dog; Moderate activity.,Other,6687480.0,
191,59472,7,2,,103164951,4946,Unspecified,,,,,Beta adrenergic blockade activity was measured in anesthetized dogs by blockade of isoproterenol induced hypotension after iv administration,Other,6102151.0,
192,59473,7,2,,103164951,4946,Unspecified,,,,,Beta adrenergic blockade activity was measured in anesthetized dogs by blockade of isoproterenol induced tachycardia after iv administration,Other,6102151.0,
193,60110,3,3,,103164951,4946,Unspecified,,,,,Number of dogs reverted ouabain induced arrhythmia,Other,7359531.0,
194,60112,3,3,,103164951,4946,Unspecified,,,,,Number of dogs used ouabain induced arrhythmia,Other,7359531.0,
195,60426,3,3,,103164951,4946,Unspecified,,,,,Concentration of ouabain required to induce arrhythmia in dogs,Other,7359531.0,
196,60471,3,3,,103164951,4946,Unspecified,,,,,Evaluated for the dose required to achieve 50 % of the maximal cardiac slowing in the triazine tachycardia test.,Other,6687480.0,
197,60485,3,7,,103164951,4946,Unspecified,,,,,Relative adrenoceptor blocking activity (DR10) was recorded for the antagonism of Isoproterenol-induced responses in Positive chronotropy in beta1-Adrenoceptor blockade,Other,6124636.0,
198,60615,3,11,,103164951,4946,Unspecified,1703760.0,403910.0,,,Relative adrenoceptor blocking activity (DR10) was recorded for the antagonism of Isoproterenol-induced responses in Vasodepression in beta2-Adrenoceptor blockade.,Other,6124636.0,
199,60896,5,3,,103164951,4946,Unspecified,,,,,Percent inhibition of isoproterenol induced tachycardia at a dose of 1.3 microg (3-h infusion period),Other,6146718.0,
200,61087,5,2,,103164951,4946,Active,,,0.02512,Kd,Compound was tested for its ability to block isoproterenol-induced contractile force in anesthetized dogs.,Confirmatory,6115057.0,
201,61088,5,3,,103164951,4946,Active,,,0.03715,Kd,Compound was tested for its ability to block isoproterenol-induced increases in heart rate(HR) in anesthetized dogs.,Confirmatory,6115057.0,
202,61089,5,2,,103164951,4946,Active,,,0.01122,Kd,Compound was tested for its ability to block isoproterenol-induced vasodilation in anesthetized dogs.,Confirmatory,6115057.0,
203,62112,3,4,,103164951,4946,Unspecified,,,,,Evaluated for the heart rate at dose 0.5 mg/kg in 4 animals by poldine tachycardia test,Other,6687480.0,
204,62114,3,4,,103164951,4946,Unspecified,,,,,Evaluated for the heart rate at dose 1.0 mg/kg in 4 animals by aminophylline-induced sinus tachycardia test,Other,6687480.0,
205,62115,3,4,,103164951,4946,Unspecified,,,,,Evaluated for the heart rate at dose 1.0 mg/kg in 4 animals by glucagon-induced tachycardia test,Other,6687480.0,
206,62116,3,4,,103164951,4946,Unspecified,,,,,Evaluated for the heart rate at dose 1.0 mg/kg in 4 animals by poldine tachycardia test,Other,6687480.0,
207,62120,3,4,,103164951,4946,Unspecified,,,,,Evaluated for the heart rate at dose 2.5 mg/kg in 4 animals by aminophylline-induced sinus tachycardia test,Other,6687480.0,
208,62237,3,4,,103164951,4946,Unspecified,,,,,Evaluated for the heart rate at dose 2.5 mg/kg in 4 animals by glucagon-induced tachycardia test,Other,6687480.0,
209,62238,3,4,,103164951,4946,Unspecified,,,,,Evaluated for the heart rate at dose 2.5 mg/kg in 4 animals by poldine tachycardia test,Other,6687480.0,
210,62242,3,4,,103164951,4946,Unspecified,,,,,Evaluated for the heart rate at dose 5.0 mg/kg in 4 animals by aminophylline-induced sinus tachycardia test,Other,6687480.0,
211,62986,3,3,,103164951,4946,Unspecified,,,,,"Effect on ischemic arrhythmias was studied in dogs, by glass bead method. 60 mg/kg was administered perorally and percent sinus beats after compound administration, was reported.",Other,6147415.0,
212,62987,3,3,,103164951,4946,Unspecified,,,,,"Effect on ischemic arrhythmias was studied in dogs, by glass bead method. 60 mg/kg was administered perorally and percent sinus beats before compound administration, was reported.",Other,6147415.0,
213,62988,3,3,,103164951,4946,Unspecified,,,,,"Effect on ischemic arrhythmias was studied in dogs. 10 mg/kg was injected intravenously and percent sinus beats after compound administration, was reported.",Other,6147415.0,
214,62989,3,3,,103164951,4946,Unspecified,,,,,"Effect on ischemic arrhythmias was studied in dogs. 10 mg/kg was injected intravenously and percent sinus beats before compound administration, was reported.",Other,6147415.0,
215,63493,5,3,,103164951,4946,Active,,,0.00155,Kd,Evaluated for Adrenoceptor from guinea pig left atrium by using isoproterenol as agonist.,Confirmatory,6124636.0,
216,63494,5,3,,103164951,4946,Active,,,0.00468,Kd,Evaluated for Adrenoceptor from guinea pig trachea by using isoproterenol as agonist.,Confirmatory,6124636.0,
217,63503,5,2,,103164951,4946,Unspecified,,,,,"Concentration that causes a 20% increase in APD95 (action potential duration at 95% repolarization) from control value in anesthetized dogs; (-)1.0, (-)3.5, (-)2.5",Other,1976812.0,
218,65625,7,1,,103164951,4946,Unspecified,,,5.0,Ki,Tested for binding affinity against dopamine receptor D3 expressed in Sf9 cells.,Confirmatory,8098771.0,
219,65751,8,5,,103164951,4946,Unspecified,47117674.0,24318.0,10.0,Ki,Competitive binding assay against Dopamine receptor D2 in rat striatal membranes and [125I]-IBF radioligand,Confirmatory,2136916.0,
220,65880,7,1,,103164951,4946,Active,,,12.902000000000001,Ki,Inhibitory constant against binding of [125I]- IBZM to D2 receptor in rat striatal membrane,Confirmatory,2966245.0,
221,75207,3,3,,103164951,4946,Inconclusive,,,,,Cardioselectivity (Antilog [pA2 (atria) / pA2 (trachea)] );ND means no data.,Other,6135805.0,
222,76043,3,3,,103164951,4946,Unspecified,,,,,Less than 80% recovery from 50% blockade levels after 1-h infusions of drug(in vivo),Other,6135805.0,
223,76940,6,3,,103164951,4946,Unspecified,,,,,Decrease in diastolic blood pressure in anesthetized guinea pigs induced with urethane.,Other,6145801.0,
224,77095,8,1,,103164951,4946,Active,,,0.01,ED50,In vitro evaluation on guinea pig trachea. EC50 which is the molar concentration required to give 50% inhibition of the isoproterenol response (1x10E-6M) was determined.,Confirmatory,6145801.0,
225,77257,6,3,,103164951,4946,Unspecified,,,,,Mean increase in the heart rate in anesthetized guinea pigs induced with urethane.,Other,6145801.0,
226,78357,3,3,,103164951,4946,Unspecified,,,,,Effect on maximal follow rate showing the contractile frequencies of atria to electrical stimulation 10 min after incubating compound with right atria of guinea pig,Other,6147415.0,
227,79324,6,6,,103164951,4946,Active,81914759.0,100722663.0,0.00339,Kd,"Antagonism of isoprenaline-induced relaxation of guinea pig tracheal chains, contracted with carbachol",Confirmatory,2903245.0,
228,79325,6,2,,103164951,4946,Active,,,0.0024,Kd,Antagonism of the isoprenaline-induced positive chronotropic effect on the atria of guinea pig,Confirmatory,6104730.0,
229,79515,5,2,,103164951,4946,Active,,,0.002,Kd,Negative log concentration effecting 50% blockade of isoproterenol-induced rate responses in vitro in guinea pig right atria.,Confirmatory,6135805.0,
230,79518,6,3,,103164951,4946,Active,,,0.00759,Kd,Positive chronotropic effect was evaluated on atrial muscles of the guinea pig,Confirmatory,7908697.0,
231,79519,6,3,,103164951,4946,Active,,,0.0038,Kd,Positive inotropic effect was evaluated on atrial muscles of the guinea pig,Confirmatory,7908697.0,
232,79647,6,6,,103164951,4946,Active,81914759.0,100722663.0,0.00339,Kd,The apparent pA2 value was measured for beta-2 adrenergic blocking activity on the trachea of guinea pig,Confirmatory,6104730.0,
233,79651,6,2,,103164951,4946,Unspecified,,,,Kd,Ability to block Beta-1 adrenergic receptor in guinea pig right atria preparation at a duration of 3h,Confirmatory,6130154.0,
234,79652,6,2,,103164951,4946,Unspecified,,,,Kd,Ability to block Beta-1 adrenergic receptor in guinea pig right atria preparation at a duration of 40 min,Confirmatory,6130154.0,
235,79687,5,3,,103164951,4946,Active,,,0.007940000000000001,Kd,Ionotropic effect in electrically driven left atrial preparation (Atria isolated from guinea pig) and is expressed in pA2.,Confirmatory,9572886.0,
236,80447,5,2,,103164951,4946,Active,,,0.0050100000000000006,Kd,Chronotropic effect studied in right atria isolated from guinea pig and is expressed in pA2.,Confirmatory,9572886.0,
237,80626,5,3,,103164951,4946,Active,,,0.00126,Kd,Inhibition of isoproterenol-induced responses in guinea pig trachea.,Confirmatory,6135805.0,
238,91481,4,7,,103164951,4946,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
239,92844,6,2,,103164951,4946,Unspecified,,,178.4,IC50,Concentration required to inhibit ADP-induced platelet aggregation by 50%,Confirmatory,1501222.0,
240,127068,3,4,,103164951,4946,Active,,,,,"Compound was evaluated for ventricular extrasystole activity, 3 min before aconitine infusion, at a dose of 10 mg/kg, intravenously administered in mice; S=significant antiarrhythmic effect",Other,6147415.0,
241,127205,3,4,,103164951,4946,Active,,,,,"Compound was evaluated for ventricular extrasystole, 30 min before aconitine infusion, at a dose of 30 mg/kg, perorally administered in mice; S=significant antiarrhythmic effect",Other,6147415.0,
242,127207,3,4,,103164951,4946,Active,,,,,"Compound was evaluated for ventricular tachycardia activity in intravenously administered mice, 3 min before aconitine infusion, at a dose of 10 mg/kg; S=significant antiarrhythmic effect",Other,6147415.0,
243,134406,6,2,,103164951,4946,Unspecified,,,,,Lethal dose in mice (LD50) (following i.v. dosing),Other,6147415.0,
244,150618,9,2,,103164951,4946,Unspecified,,,573.0,IC50,Concentration required for 50% inhibition at binding site of human P-Glycoprotein (P-gp) in one-affinity model,Confirmatory,12477351.0,
245,150735,9,2,,103164951,4946,Active,,,48.0,Ki,High affinity constant at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Confirmatory,12477351.0,
246,150736,3,8,,103164951,4946,Unspecified,,,,,Fraction of high affinity at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Other,12477351.0,
247,156202,3,4,,103164951,4946,Unspecified,,,,,Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system,Other,10841786.0,
248,156204,3,4,,103164951,4946,Unspecified,,,,,Binding to POPC/GMI liposomes using biosensor system,Other,10841786.0,
249,159424,6,7,,103164951,4946,Unspecified,5921171.0,397355.0,,,Tested for beta-1 adrenoceptor blocking activity in anesthetized pigs (n=2) challenged with intravenous injections of isoproterenol.,Other,2435902.0,
250,159425,6,7,,103164951,4946,Unspecified,3023358.0,397357.0,,,Tested for beta-2 adrenoceptor blocking activity in anesthetized pigs (n=2) challenged with intravenous injections of isoproterenol.,Other,2435902.0,
251,165560,7,1,,103164951,4946,Unspecified,,,,,Biodistribution pattern of [123I]- ligand was evaluated in blood of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
252,165674,6,1,,103164951,4946,Unspecified,,,,,Biodistribution pattern of [123I]- ligand was evaluated in fat of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
253,165681,6,1,,103164951,4946,Unspecified,,,,,Biodistribution pattern of [123I]- ligand was evaluated in intestine of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
254,165693,6,1,,103164951,4946,Unspecified,,,,,Biodistribution pattern of [123I]- ligand was evaluated in left atrial muscle of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
255,165700,6,1,,103164951,4946,Unspecified,,,,,Biodistribution pattern of [123I]- ligand was evaluated in left ventricular muscle of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
256,165796,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 0 min administration (1%) of compound,Other,2891852.0,
257,165797,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 0 min administration (2.5%) of compound,Other,2891852.0,
258,165801,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 2 hr administration (1%) of compound,Other,2891852.0,
259,165802,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 2 hr administration (2.5%) of compound,Other,2891852.0,
260,165804,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 30 min administration (1%) of compound,Other,2891852.0,
261,165805,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 30 min administration (2.5%) of compound,Other,2891852.0,
262,165807,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 3h administration (1%) of compound,Other,2891852.0,
263,165808,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 3h administration (2.5%) of compound,Other,2891852.0,
264,165810,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 4 hr administration (1%) of compound,Other,2891852.0,
265,165811,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 4 hr administration (2.5%) of compound,Other,2891852.0,
266,165815,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 60 min administration (1%) of compound,Other,2891852.0,
267,165816,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 60 min administration (2.5%) of compound,Other,2891852.0,
268,165817,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 6 hr administration (1%) of compound,Other,2891852.0,
269,165818,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 6 hr administration (2.5%) of compound,Other,2891852.0,
270,165820,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 8 hr administration (1%) of compound,Other,2891852.0,
271,165821,3,3,,103164951,4946,Unspecified,,,,,Percentage change of IOP in rabbits after 8 hr administration (2.5%) of compound,Other,2891852.0,
272,165835,6,1,,103164951,4946,Unspecified,,,,,Biodistribution pattern of [123I]- ligand was evaluated in liver of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
273,165842,6,1,,103164951,4946,Unspecified,,,,,Biodistribution pattern of [123I]- ligand was evaluated in lung of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
274,165849,6,1,,103164951,4946,Unspecified,,,,,Biodistribution pattern of [123I]- ligand was evaluated in muscle of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
275,165856,6,1,,103164951,4946,Unspecified,,,,,Biodistribution pattern of [123I]- ligand was evaluated in right atrial muscle of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
276,165863,6,1,,103164951,4946,Unspecified,,,,,Biodistribution pattern of [123I]- ligand was evaluated in right ventricular muscle of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
277,165949,6,2,,103164951,4946,Unspecified,,,,,Concentration in aqueous humor of rabbit after 120 min administration of compound; Below detection limit,Other,2891852.0,
278,165950,3,3,,103164951,4946,Unspecified,,,,,Concentration in aqueous humor of rabbit after 30 min administration of compound,Other,2891852.0,
279,165952,3,3,,103164951,4946,Unspecified,,,,,Concentration in aqueous humor of rabbit after 60 min administration of compound,Other,2891852.0,
280,165955,5,3,,103164951,4946,Unspecified,,,,,Concentration in cornea of rabbit after 120 min administration of compound; Below detection limit,Other,2891852.0,
281,165956,3,4,,103164951,4946,Unspecified,,,,,Concentration in cornea of rabbit after 30 min administration of compound,Other,2891852.0,
282,165958,3,4,,103164951,4946,Unspecified,,,,,Concentration in cornea of rabbit after 60 min administration of compound,Other,2891852.0,
283,165960,5,2,,103164951,4946,Unspecified,,,,,Concentration in iris -ciliary body of rabbit after 120 min administration of compound; Below detection limit,Other,2891852.0,
284,165964,3,3,,103164951,4946,Unspecified,,,,,Concentration in iris-ciliary body of rabbit after 30 min administration of compound,Other,2891852.0,
285,165965,5,2,,103164951,4946,Inconclusive,,,,,Concentration in iris-ciliary body of rabbit after 60 min administration of compound; Below detection limit,Other,2891852.0,
286,165973,5,2,,103164951,4946,Inactive,,,,,Concentration of propranolone oxime in aqueous humor of rabbit after 120 min administration of compound; N/A= no oxime can be present after administration of propranolone hydrochloride,Other,2891852.0,
287,165975,5,2,,103164951,4946,Inactive,,,,,Concentration of propranolone oxime in aqueous humor of rabbit after 30 min administration of compound; N/A= no oxime can be present after administration of propranolone hydrochloride,Other,2891852.0,
288,165977,5,2,,103164951,4946,Inactive,,,,,Concentration of propranolone oxime in aqueous humor of rabbit after 60 min administration of compound; N/A= no oxime can be present after administration of propranolone hydrochloride,Other,2891852.0,
289,165984,6,1,,103164951,4946,Unspecified,,,,,Biodistribution pattern of [123I]- ligand was evaluated in spleen of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
290,165992,6,1,,103164951,4946,Unspecified,,,,,Cerebral biodistribution pattern of [123I]- ligand was evaluated in cerebellum of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
291,165999,6,1,,103164951,4946,Unspecified,,,,,Cerebral biodistribution pattern of [123I]- ligand was evaluated in frontal cortex of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
292,166005,6,1,,103164951,4946,Unspecified,,,,,Cerebral biodistribution pattern of [123I]- ligand was evaluated in hypothalamus of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
293,166085,5,3,,103164951,4946,Inactive,,,,,Concentration of propranolone oxime in cornea of rabbit after 120 min administration of compound; N/A= no oxime can be present after administration of propranolone hydrochloride,Other,2891852.0,
294,166087,5,3,,103164951,4946,Inactive,,,,,Concentration of propranolone oxime in cornea of rabbit after 30 min administration of compound; N/A= no oxime can be present after administration of propranolone hydrochloride,Other,2891852.0,
295,166089,5,3,,103164951,4946,Inactive,,,,,Concentration of propranolone oxime in cornea of rabbit after 60 min administration of compound; N/A= no oxime can be present after administration of propranolone hydrochloride,Other,2891852.0,
296,166090,5,2,,103164951,4946,Inactive,,,,,Concentration of propranolone oxime in iris-ciliary body of rabbit after 120 min administration of compound; N/A= no oxime can be present after administration of propranolone hydrochloride,Other,2891852.0,
297,166092,5,2,,103164951,4946,Inactive,,,,,Concentration of propranolone oxime in iris-ciliary body of rabbit after 30 min administration of compound; N/A= no oxime can be present after administration of propranolone hydrochloride,Other,2891852.0,
298,166094,5,2,,103164951,4946,Inactive,,,,,Concentration of propranolone oxime in iris-ciliary body of rabbit after 60 min administration of compound; N/A= no oxime can be present after administration of propranolone hydrochloride,Other,2891852.0,
299,166127,6,1,,103164951,4946,Unspecified,,,,,Cerebral biodistribution pattern of [123I]- ligand was evaluated in kidney of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
300,166130,6,1,,103164951,4946,Unspecified,,,,,Cerebral biodistribution pattern of [123I]- ligand was evaluated in pituitary gland of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
301,166137,6,1,,103164951,4946,Unspecified,,,,,Cerebral biodistribution pattern of [123I]- ligand was evaluated in striatum of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
302,166144,6,1,,103164951,4946,Unspecified,,,,,Cerebral biodistribution pattern of [123I]- ligand was evaluated in thalamus of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr,Other,8765508.0,
303,166290,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 0 min after administration (2.5%),Other,2891852.0,
304,166291,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 0 min after administration (1%),Other,2891852.0,
305,166293,4,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 2 hr after administration (1%),Other,2891852.0,
306,166294,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 2 hr after administration (2.5%),Other,2891852.0,
307,166296,4,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 30 mins after administration (1%),Other,2891852.0,
308,166297,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 30 mins after administration (2.5%),Other,2891852.0,
309,166298,4,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 3h after administration (1%),Other,2891852.0,
310,166299,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 3h after administration (2.5%),Other,2891852.0,
311,166300,4,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 4 hr after administration (1%),Other,2891852.0,
312,166301,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 4 hr after administration (2.5%),Other,2891852.0,
313,166304,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 60 mins after administration (2.5%),Other,2891852.0,
314,166305,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 60 min after administration (1%),Other,2891852.0,
315,166307,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 6 hr min after administration (1%),Other,2891852.0,
316,166308,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 6 hr min after administration (2.5%),Other,2891852.0,
317,166310,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 8 hr min after administration (1%),Other,2891852.0,
318,166311,3,4,,103164951,4946,Unspecified,,,,,Effect on IOP of rabbits 8 hr min after administration (2.5%),Other,2891852.0,
319,168612,3,3,,103164951,4946,Unspecified,,,,,Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed as urinary output. at a dose of 128 mg/kg; 9.05/12.83,Other,3001305.0,
320,168617,3,3,,103164951,4946,Unspecified,,,,,Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed as urinary output. at a dose of 16 mg/kg; 9.05/9.87,Other,3001305.0,
321,168626,3,3,,103164951,4946,Unspecified,,,,,Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed as urinary output. at a dose of 32 mg/kg; 9.05/10.98,Other,3001305.0,
322,168635,3,3,,103164951,4946,Unspecified,,,,,Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed as urinary output. at a dose of 64 mg/kg; 9.05/11.67,Other,3001305.0,
323,168803,3,4,,103164951,4946,Unspecified,,,,,"Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed in Na+, mequiv/6 hr at a dose of 128 mg/kg; 0.216/0.263",Other,3001305.0,
324,168811,3,4,,103164951,4946,Unspecified,,,,,"Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed in Na+, mequiv/6 hr at a dose of 16 mg/kg; 0.216/0.178",Other,3001305.0,
325,168820,3,4,,103164951,4946,Unspecified,,,,,"Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed in Na+, mequiv/6 hr at a dose of 32 mg/kg; 0.216/0.207",Other,3001305.0,
326,168827,3,4,,103164951,4946,Unspecified,,,,,"Compound was tested for oral salidiuretic activity (control/drug treatment value) in rats expressed in Na+, mequiv/6 hr at a dose of 64 mg/kg; 0.216/0.097",Other,3001305.0,
327,170444,3,4,,103164951,4946,Unspecified,,,,,Antihypertensive activity in spontaneously hypertensive rats after peroral administration,Other,6102605.0,
328,171500,4,4,,103164951,4946,Unspecified,,,,,Blood pressure of the urethane-anesthetized normotensive Wistar rat was tested 10 min after inducing the compound on dose of 1.0 mg/kg,Other,7908697.0,
329,171501,4,4,,103164951,4946,Unspecified,,,,,Blood pressure of the urethane-anesthetized normotensive Wistar rat was tested 15 min after inducing the compound on dose of 1.0 mg/kg,Other,7908697.0,
330,171502,4,4,,103164951,4946,Unspecified,,,,,Blood pressure of the urethane-anesthetized normotensive Wistar rat was tested 30 min after inducing the compound on dose of 1.0 mg/kg,Other,7908697.0,
331,171503,4,4,,103164951,4946,Unspecified,,,,,Blood pressure of the urethane-anesthetized normotensive Wistar rat was tested 5 min after inducing the compound on dose of 1.0 mg/kg,Other,7908697.0,
332,171630,4,4,,103164951,4946,Unspecified,,,,,Blood pressure of the urethane-anesthetized normotensive Wistar rat was tested 60 min after inducing the compound on dose of 1.0 mg/kg,Other,7908697.0,
333,174223,5,3,,103164951,4946,Inactive,,,,,Systolic blood pressure (SBP) in anesthetized spontaneously hypertensive rats(SHR) at 7.5 hours after administration of 75 mg/kg dose intravenously; NS is not statistically significant,Other,2909730.0,
334,174416,3,4,,103164951,4946,Unspecified,,,,,Change in systolic blood pressure after 100 mg/kg oral administration in spontaneous hypertensive rats after 24 hr,Other,7310823.0,
335,174417,3,4,,103164951,4946,Unspecified,,,,,Change in systolic blood pressure after 100 mg/kg oral administration in spontaneous hypertensive rats after 2 hr,Other,7310823.0,
336,174418,3,4,,103164951,4946,Unspecified,,,,,Change in systolic blood pressure after 100 mg/kg oral administration in spontaneous hypertensive rats after 4 hr,Other,7310823.0,
337,174556,3,4,,103164951,4946,Unspecified,,,,,Change in systolic blood pressure after 33 mg/kg oral administration in spontaneous hypertensive rats after 24 hr,Other,7310823.0,
338,174557,3,4,,103164951,4946,Unspecified,,,,,Change in systolic blood pressure after 33 mg/kg oral administration in spontaneous hypertensive rats after 2 hr,Other,7310823.0,
339,174558,3,4,,103164951,4946,Unspecified,,,,,Change in systolic blood pressure after 33 mg/kg oral administration in spontaneous hypertensive rats after 4 hr,Other,7310823.0,
340,176311,6,2,,103164951,4946,Unspecified,,,,,Beta-1-adrenoceptor blockade measured as inhibition of tachycardia caused by isoprenaline in anesthetized rats when administered intravenously,Other,6138434.0,
341,176761,6,8,,103164951,4946,Unspecified,114754.0,24925.0,,,In vivo beta adrenergic receptor blocking potency was determined by inhibition of tachycardia in rat,Other,6130155.0,
342,176761,6,8,,103164951,4946,Unspecified,114768.0,24176.0,,,In vivo beta adrenergic receptor blocking potency was determined by inhibition of tachycardia in rat,Other,6130155.0,
343,176761,6,8,,103164951,4946,Unspecified,543882.0,25645.0,,,In vivo beta adrenergic receptor blocking potency was determined by inhibition of tachycardia in rat,Other,6130155.0,
344,177022,4,9,,103164951,4946,Unspecified,114754.0,24925.0,,,Beta-1 adrenergic receptor agonist activity as increased heart rate by 30 beats/min in rats,Other,2866246.0,
345,177960,7,7,,103164951,4946,Unspecified,114754.0,24925.0,,,Antagonistic activity against beta-1 adrenergic receptor to inhibit tachycardia in rats,Other,2866246.0,
346,180095,7,1,,103164951,4946,Unspecified,,,,,Heart rate of the urethane-anesthetized normotensive Wistar rat was tested 10 min after inducing the compound on dose of 1.0 mg/kg,Other,7908697.0,
347,180096,7,1,,103164951,4946,Unspecified,,,,,Heart rate of the urethane-anesthetized normotensive Wistar rat was tested 15 min after inducing the compound on dose of 1.0 mg/kg,Other,7908697.0,
348,180097,7,1,,103164951,4946,Unspecified,,,,,Heart rate of the urethane-anesthetized normotensive Wistar rat was tested 30 min after inducing the compound on dose of 1.0 mg/kg,Other,7908697.0,
349,180098,7,1,,103164951,4946,Unspecified,,,,,Heart rate of the urethane-anesthetized normotensive Wistar rat was tested 5 min after inducing the compound on dose of 1.0 mg/kg,Other,7908697.0,
350,180099,7,1,,103164951,4946,Unspecified,,,,,Heart rate of the urethane-anesthetized normotensive Wistar rat was tested 60 min after inducing the compound on dose of 1.0 mg/kg,Other,7908697.0,
351,181812,7,2,,103164951,4946,Inactive,,,,,Percentage of fall in systolic blood pressure (SBP) at the following hours after dosing at 75 mg/kg (po) at 24 hr in spontaneously hypertensive rats(SHR); NS means not significant,Other,2883317.0,
352,181815,7,2,,103164951,4946,Inactive,,,,,Percentage of fall in systolic blood pressure (SBP) at the following hours after dosing at 75 mg/kg (po) at 2 hr in spontaneously hypertensive rats(SHR); NS means not significant,Other,2883317.0,
353,181817,7,2,,103164951,4946,Inactive,,,,,Percentage of fall in systolic blood pressure (SBP) at the following hours after dosing at 75 mg/kg (po) at 5 hr in spontaneously hypertensive rats(SHR); NS means not significant,Other,2883317.0,
354,181820,7,2,,103164951,4946,Inactive,,,,,Percentage of fall in systolic blood pressure (SBP) at the following hours after dosing at 75 mg/kg (po) at 7.5 hr in spontaneously hypertensive rats(SHR); NS means not significant,Other,2883317.0,
355,184270,3,4,,103164951,4946,Unspecified,,,,,The compound was tested for percent increase in heart rate with respect to that measured after isoprenaline in 5-10 animals.,Other,9572886.0,
356,185135,3,7,,103164951,4946,Unspecified,114754.0,24925.0,,,Beta blocking effect as percent inhibition of increased heart frequency induced by isoprenaline in 5-10 animals.,Other,9572886.0,
357,185135,3,7,,103164951,4946,Unspecified,114768.0,24176.0,,,Beta blocking effect as percent inhibition of increased heart frequency induced by isoprenaline in 5-10 animals.,Other,9572886.0,
358,185135,3,7,,103164951,4946,Unspecified,543882.0,25645.0,,,Beta blocking effect as percent inhibition of increased heart frequency induced by isoprenaline in 5-10 animals.,Other,9572886.0,
359,185196,3,3,,103164951,4946,Unspecified,,,,,"Tested for MED (smallest dose giving maximum effect) evaluated by dose-response curve, from 0.1 to 5 mg/kg in 5-10 animals on iv administration.",Other,9572886.0,
360,186078,3,3,,103164951,4946,Unspecified,,,,,"Compound was tested for effect on arterial pressure in spontaneously hypertensive rats (SHR) at 5 mg/kg, po",Other,6113285.0,
361,186642,3,3,,103164951,4946,Unspecified,,,,,Evaluated for its positive inotropic effect by the beta-adrenergic stimulation on cyclic AMP concentrations in rat left atria at 10E-7 concentration,Other,6319701.0,
362,187013,3,3,,103164951,4946,Unspecified,,,,,Tested for maximum fall in mean arterial pressure in Spontaneously hypertensive rats after peroral administration by using 1% methyl cellulose as vehicle at 1.25 mg/kg,Other,6102151.0,
363,187015,3,3,,103164951,4946,Unspecified,,,,,Tested for maximum fall in mean arterial pressure in Spontaneously hypertensive rats after peroral administration by using 1% methyl cellulose as vehicle at 20 mg/kg,Other,6102151.0,
364,187017,4,3,,103164951,4946,Unspecified,,,,,Tested for maximum fall in mean arterial pressure in Spontaneously hypertensive rats after peroral administration by using 1% methyl cellulose as vehicle at 5 mg/kg,Other,6102151.0,
365,187178,4,3,,103164951,4946,Unspecified,,,5.0,Ki,Inhibition constant of compound on R-(+)-125[I]-8 radioligand binding to rat striatal membranes,Confirmatory,1825848.0,
366,190410,4,4,,103164951,4946,Unspecified,,,,,Antihypertensive activity expressed as percentage of base-line systolic blood pressure of base-line values in spontaneously hypertensive rats (SHR) was reported after 24 hr,Other,2884312.0,
367,190411,4,4,,103164951,4946,Unspecified,,,,,Antihypertensive activity expressed as percentage of base-line systolic blood pressure of base-line values in spontaneously hypertensive rats (SHR) was reported after 2 hr,Other,2884312.0,
368,190412,4,4,,103164951,4946,Unspecified,,,,,Antihypertensive activity expressed as percentage of base-line systolic blood pressure of base-line values in spontaneously hypertensive rats (SHR) was reported after 4 hr,Other,2884312.0,
369,192052,3,4,,103164951,4946,Unspecified,,,,,Percentage decrease in systolic blood pressure (SBP) for compound-treated group relative to the value for untreated control at 75 mg/kg dose (po) in spontaneously hypertensive rats(SHR),Other,2883317.0,
370,192444,4,4,,103164951,4946,Unspecified,,,,,Systolic blood pressure (SBP) in anesthetized spontaneously hypertensive rats (SHR) before administration of 75 mg/kg dose perorally.,Other,2909730.0,
371,192643,3,3,,103164951,4946,Unspecified,,,,,"Dose required to induce at least 50% inhibition of the isoprenaline-induced effect, administered intravenously",Other,6120237.0,
372,193030,5,3,,103164951,4946,Inconclusive,,,,,Antihypertensive activity as percent average (over 24 hr) decrease in blood pressure at 135 umol/kg po (~40-50 mg/kg) in 5 spontaneously hypertensive rats (SHR); NA denotes no data,Other,2435902.0,
373,193033,5,3,,103164951,4946,Inconclusive,,,,,Antihypertensive activity as percent maximum (0-6 hr) decrease in blood pressure at 135 umol/kg po (~40-50 mg/kg) in 5 spontaneously hypertensive rats (SHR); NA denotes no data,Other,2435902.0,
374,193105,3,10,,103164951,4946,Unspecified,114754.0,24925.0,,,Beta-adrenergic receptor blockade activity in conscious normotensive rats at a dose of 1.25 mg/kg,Other,6102605.0,
375,193105,3,10,,103164951,4946,Unspecified,114768.0,24176.0,,,Beta-adrenergic receptor blockade activity in conscious normotensive rats at a dose of 1.25 mg/kg,Other,6102605.0,
376,193105,3,10,,103164951,4946,Unspecified,543882.0,25645.0,,,Beta-adrenergic receptor blockade activity in conscious normotensive rats at a dose of 1.25 mg/kg,Other,6102605.0,
377,193107,3,10,,103164951,4946,Unspecified,114754.0,24925.0,,,The compound was tested for beta-adrenergic receptor blockade activity in conscious normotensive rats at a dose of 5 mg/kg,Other,6102605.0,
378,193107,3,10,,103164951,4946,Unspecified,114768.0,24176.0,,,The compound was tested for beta-adrenergic receptor blockade activity in conscious normotensive rats at a dose of 5 mg/kg,Other,6102605.0,
379,193107,3,10,,103164951,4946,Unspecified,543882.0,25645.0,,,The compound was tested for beta-adrenergic receptor blockade activity in conscious normotensive rats at a dose of 5 mg/kg,Other,6102605.0,
380,193230,3,3,,103164951,4946,Unspecified,,,,,Duration of action of compound was determined for antihypertensive action in rats,Other,6120237.0,
381,193870,3,4,,103164951,4946,Unspecified,,,,,Change in diastolic blood pressure in anesthetized spontaneous hypertensive rats when 5 mg/kg of compound was administered intravenously,Other,6120237.0,
382,193881,4,4,,103164951,4946,Unspecified,,,,,Change in systolic blood pressure in anesthetized spontaneous hypertensive rats when 5 mg/kg of compound was administered intravenously,Other,6120237.0,
383,194405,3,4,,103164951,4946,Unspecified,,,,,Vasodilator activity in ganglion blocked rats. Values denote percent change in mean arterial blood pressure 30 minutes after dosing rats at 3 mg/kg intravenously,Other,6102605.0,
384,194448,3,3,,103164951,4946,Unspecified,,,,,"Evaluated for the percentage inhibition of the depressor response of isoproterenol (0.25 mg/kg, iv) by propranolol hydrochloride at dose of 10 mg/kg",Other,2883317.0,
385,196437,4,4,,103164951,4946,Unspecified,,,10.0,Ki,Inhibition constant on radiolabeled [125I]FIDA1 binding to rat striatal membranes,Confirmatory,8093734.0,
386,205268,4,7,,103164951,4946,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
387,211857,6,3,,103164951,4946,Unspecified,,,,,Compound was tested for its toxicity after intravenous administration to mice in experiment 1,Other,,
388,211859,6,3,,103164951,4946,Unspecified,,,,,Compound was tested for its toxicity after intravenous administration to mice in experiment 2,Other,,
389,211863,6,3,,103164951,4946,Unspecified,,,,,Compound was tested for its toxicity after oral administration to mice in experiment 1,Other,,
390,211865,6,3,,103164951,4946,Unspecified,,,,,Compound was tested for its toxicity after oral administration to mice in experiment 2,Other,,
391,218533,6,8,,103164951,4946,Unspecified,114754.0,24925.0,,,beta-adrenoceptor blocking activity of the perorally administered compound was evaluated by inhibition of isiprenaline-induced tachycardia in rats,Other,8093626.0,
392,218533,6,8,,103164951,4946,Unspecified,114768.0,24176.0,,,beta-adrenoceptor blocking activity of the perorally administered compound was evaluated by inhibition of isiprenaline-induced tachycardia in rats,Other,8093626.0,
393,218533,6,8,,103164951,4946,Unspecified,543882.0,25645.0,,,beta-adrenoceptor blocking activity of the perorally administered compound was evaluated by inhibition of isiprenaline-induced tachycardia in rats,Other,8093626.0,
394,218704,9,2,,103164951,4946,Active,,,0.0065,Ki,Evaluated for beta-receptor affinity determined in rat brain membrane fraction with [3H]- dihydroalprenolol,Confirmatory,2883317.0,
395,218718,7,1,,103164951,4946,Active,,,0.0023,Ki,Inhibition of [3H]dihydroalprenolol binding to beta 1 adrenoceptor from turkey erythrocyte membranes.,Confirmatory,8093626.0,
396,220928,6,8,,103164951,4946,Unspecified,114754.0,24925.0,,,Beta-adrenoceptor blocking activity after intravenous dose as inhibition of isiprenaline-induced tachycardia in rats,Other,8093626.0,
397,220928,6,8,,103164951,4946,Unspecified,114768.0,24176.0,,,Beta-adrenoceptor blocking activity after intravenous dose as inhibition of isiprenaline-induced tachycardia in rats,Other,8093626.0,
398,220928,6,8,,103164951,4946,Unspecified,543882.0,25645.0,,,Beta-adrenoceptor blocking activity after intravenous dose as inhibition of isiprenaline-induced tachycardia in rats,Other,8093626.0,
399,223361,3,3,,103164951,4946,Active,,,,,Inhibition of the isoproterenol response at a dose of 1 x 10e -4M in guinea pig; slight inhibition was found.,Other,2909730.0,
400,227718,7,1,,103164951,4946,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
401,227878,3,7,,103164951,4946,Unspecified,,,,,Broncho-selectivity for beta-2 and beta-1 adrenergic receptor (difference between the tracheal and atrial pA2 values),Other,6148422.0,
402,229400,3,5,,103164951,4946,Unspecified,,,,,"Selectivity of inhibition at beta-1 versus beta-2 adrenergic receptors, ratio of pA2 values",Other,2903245.0,
403,229421,3,3,,103164951,4946,Unspecified,,,,,Selectivity ratio ED50(HR) / ED50(DBP),Other,6145801.0,
404,230146,4,6,,103164951,4946,Unspecified,,,,,The cardioselectivity ratio was obtained by taking the antilog (pA2 beta1-pA2 beta2),Other,2872332.0,
405,230147,4,6,,103164951,4946,Unspecified,,,,,The cardioselectivity ratio was obtained by taking the antilog of (pA2(beta-1)-pA2(beta2)),Other,6134834.0,
406,231662,3,6,,103164951,4946,Unspecified,,,,,Bronchoselectivity measured as the antilog of the difference between the tracheal and atrial pA2,Other,6104730.0,
407,231957,3,5,,103164951,4946,Unspecified,,,,,Ratio of dissociation constant KD' of rat lung to KD' of rat heart,Other,3031293.0,
408,232338,3,5,,103164951,4946,Unspecified,,,,,Ratio of rat Beta-2 to Beta-1 adrenoceptor antagonism,Other,6138434.0,
409,232339,3,7,,103164951,4946,Unspecified,,,,,Ratio of Beta-2(trachea) to Beta-1(Atria) adrenoceptor affinity constants from guinea pig,Other,6138434.0,
410,232998,3,3,,103164951,4946,Unspecified,,,,,Degree of Selectivity measured as the antilog of pA2 atria-pA2 trachea,Other,2884312.0,
411,233866,3,6,,103164951,4946,Unspecified,,,,,Selectivity determined by expression 10[pA2(atria) - pA2 (trachea)] in guinea pig,Other,6146718.0,
412,234826,4,3,,103164951,4946,Unspecified,,,,,Slope value of the compound,Other,6124636.0,
413,236268,3,4,,103164951,4946,Unspecified,,,,,Fraction absorbed in human intestine after oral administration compound was measured,Other,15658873.0,
414,236912,6,1,,103164951,4946,Unspecified,,,,,Permeability Coefficient in 2/4/A1 cell model,Other,15658873.0,
415,236913,6,1,,103164951,4946,Unspecified,,,,,Permeability Coefficient in Caco-2 cell culture model,Other,15658873.0,
416,236914,6,1,,103164951,4946,Unspecified,,,,,Permeability Coefficient in hexadecane membranes model,Other,15658873.0,
417,236916,6,1,,103164951,4946,Unspecified,,,,,Percentage of mass balance in hexadecane membranes model,Other,15658873.0,
418,236917,3,4,,103164951,4946,Unspecified,,,,,Apparent permeability of the compound was determined inCaco-2 (human colon carcinoma) cells; Activity = Papp 10E-6,Other,15689164.0,
419,236918,3,5,,103164951,4946,Unspecified,,,,,Apparent permeability of the compound was determined in MDCK (madin darby canine kidney) strain I; Activity = Papp 10e-6,Other,15689164.0,
420,237685,4,3,,103164951,4946,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
421,241889,6,7,,103164951,4946,Active,84028191.0,1565.0,1.9,IC50,Inhibitory activity against recombinant human Cytochrome P450 2D6 (CYP2D6) after incubated for 45 minutes,Confirmatory,15993593.0,
422,266006,5,1,,103164951,4946,Active,114754.0,24925.0,0.00316,Ki,Antagonist activity at rat wild type beta-1 adrenergic receptor expressed in CHO cells,Confirmatory,16759089.0,
423,266007,5,1,,103164951,4946,Active,114754.0,24925.0,0.03162,Ki,Antagonist activity at rat beta-1 adrenergic receptor Y356F mutant expressed in CHO cells,Confirmatory,16759089.0,
424,266008,5,1,,103164951,4946,Active,114754.0,24925.0,0.19952999999999999,Ki,Antagonist activity at rat beta-1 adrenergic receptor Y356A mutant expressed in CHO cells,Confirmatory,16759089.0,
425,266009,5,1,,103164951,4946,Active,114754.0,24925.0,0.01,Ki,Antagonist activity at rat beta-1 adrenergic receptor W134A mutant expressed in CHO cells,Confirmatory,16759089.0,
426,266010,5,1,,103164951,4946,Active,114754.0,24925.0,0.039810000000000005,Ki,Antagonist activity at rat beta-1 adrenergic receptor S190A mutant expressed in CHO cells,Confirmatory,16759089.0,
427,267570,3,5,,103164951,4946,Unspecified,,,,,Stability in human liver microsomes at 1 M at pH 7.4,Other,16650991.0,
428,288184,9,1,,103164951,4946,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
429,288185,7,1,,103164951,4946,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
430,288192,3,4,,103164951,4946,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
431,288193,3,4,,103164951,4946,Unspecified,,,,,"Flux ionization constant, pKa of the membrane permeability coefficient of the compound",Other,17418579.0,
432,288194,3,5,,103164951,4946,Unspecified,,,,,"Intrinsic artificial membrane permeability coefficient, log P0 of the compound",Other,17418579.0,
433,298031,3,5,,103164951,4946,Unspecified,,,,,"Lipophilicity, log D at pH7.4",Other,17725338.0,
434,298032,3,3,,103164951,4946,Unspecified,,,,,"Acid dissociation constant, pKa of the compound",Other,17725338.0,
435,298033,7,1,,103164951,4946,Unspecified,,,,,Fraction unbound ligand in rat adrenal gland after 20 hrs,Other,17725338.0,
436,298034,7,1,,103164951,4946,Unspecified,,,,,Fraction unbound ligand in rat brain after 20 hrs,Other,17725338.0,
437,298035,7,1,,103164951,4946,Unspecified,,,,,Fraction unbound ligand in rat lung after 20 hrs,Other,17725338.0,
438,298036,7,1,,103164951,4946,Unspecified,,,,,Fraction unbound ligand in rat brown fat tissue after 20 hrs,Other,17725338.0,
439,310931,3,4,,103164951,4946,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17300161.0,
440,310933,3,4,,103164951,4946,Unspecified,,,,,Permeability across PAMPA membrane after 7 hrs,Other,17300161.0,
441,311367,3,6,,103164951,4946,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
442,312895,3,4,,103164951,4946,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18189348.0,
443,312896,3,4,,103164951,4946,Unspecified,,,,,"Partition coefficient, log P by UPLC method",Other,18189348.0,
444,319635,7,1,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side in human Caco-2 cells at 10 uM,Other,18457949.0,
445,321772,7,1,,103164951,4946,Unspecified,,,,,Permeability across human Caco-2 cells,Other,18220330.0,
446,327169,3,3,,103164951,4946,Unspecified,,,,,Apparent permeability across parallel artificial membrane,Other,18348514.0,
447,327170,4,6,,103164951,4946,Unspecified,113576.0,213.0,436.51599999999996,Kd,Binding affinity to human serum albumin by PAMPA method,Confirmatory,18348514.0,
448,327171,3,3,,103164951,4946,Unspecified,,,,,Apparent permeability across parallel artificial membrane at 10 uM in presence of 50 uM human serum albumin,Other,18348514.0,
449,327172,3,3,,103164951,4946,Unspecified,,,,,Apparent permeability across parallel artificial membrane at 10 uM in presence of 100 uM human serum albumin,Other,18348514.0,
450,327173,3,3,,103164951,4946,Unspecified,,,,,Apparent permeability across parallel artificial membrane at 10 uM in presence of 300 uM human serum albumin,Other,18348514.0,
451,327174,3,3,,103164951,4946,Unspecified,,,,,Apparent permeability across parallel artificial membrane at 10 uM in presence of 600 uM human serum albumin,Other,18348514.0,
452,327175,3,3,,103164951,4946,Unspecified,,,,,Apparent permeability across parallel artificial membrane at 50 uM in presence of 100 uM human serum albumin,Other,18348514.0,
453,327176,4,6,,103164951,4946,Unspecified,113576.0,213.0,354.81300000000005,Kd,Binding affinity to 50 uM human serum albumin at 10 uM by PAMPA method,Confirmatory,18348514.0,
454,327177,4,6,,103164951,4946,Unspecified,113576.0,213.0,660.693,Kd,Binding affinity to 100 uM human serum albumin at 10 uM by PAMPA method,Confirmatory,18348514.0,
455,327178,4,6,,103164951,4946,Unspecified,113576.0,213.0,602.56,Kd,Binding affinity to 300 uM human serum albumin at 10 uM by PAMPA method,Confirmatory,18348514.0,
456,327179,4,6,,103164951,4946,Unspecified,113576.0,213.0,630.957,Kd,Binding affinity to 600 uM human serum albumin at 10 uM by PAMPA method,Confirmatory,18348514.0,
457,327180,4,6,,103164951,4946,Unspecified,113576.0,213.0,436.51599999999996,Kd,Binding affinity to 100 uM human serum albumin at 50 uM by PAMPA method,Confirmatory,18348514.0,
458,330907,10,1,,103164951,4946,Unspecified,,,,,Displacement of quinaldine red from human AAG by fluorescence method,Other,18289858.0,
459,331213,7,1,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side in human Caco-2 cells at 10 uM,Other,18487044.0,
460,332086,8,1,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco-2 cells at 10 uM,Other,18442904.0,
461,337597,3,5,,103164951,4946,Inactive,,,,,Inhibition of acetylcholine-induced contraction in guinea pig ileum at 0.2 ug/ml,Other,7798965.0,
462,343619,7,1,,103164951,4946,Unspecified,,,,,Apparent permeability across human Caco-2 cells,Other,18554907.0,
463,344616,7,1,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side in human Caco-2 cell membrane at 10 uM,Other,18722768.0,
464,350216,3,3,,103164951,4946,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19397318.0,
465,350217,3,3,,103164951,4946,Unspecified,,,,,"Octanol-water partition coefficient, log Pn of the compound",Other,19397318.0,
466,350218,3,4,,103164951,4946,Unspecified,,,,,"Octanol-water partition coefficient, log PC of the compound",Other,19397318.0,
467,350219,3,4,,103164951,4946,Unspecified,,,,,"Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 95% acetonitrile as mobile phase",Other,19397318.0,
468,350220,3,4,,103164951,4946,Unspecified,,,,,"Lipophilicity, log K at pH 2 by by hydrophilic interaction chromatography using 100% water as mobile phase",Other,19397318.0,
469,350783,7,1,,103164951,4946,Unspecified,,,,,Permeability from apical to basolateral side in human Caco-2 cells,Other,17606674.0,
470,350784,7,1,,103164951,4946,Unspecified,,,,,Permeability from basolateral to apical side in human Caco-2 cells,Other,17606674.0,
471,351392,3,3,,103164951,4946,Unspecified,,,,,Activity of Bacillus megaterium CYP450 D6H10 mutant assessed as conversion of propranolol to 5-hydroxypropranolol at 5 mM in presence of 1 mM H2O2 and 4 mM ascorbic acid,Other,19394224.0,
472,351393,3,9,,103164951,4946,Unspecified,288561879.0,,,,Activity of Agrocybe aegerita peroxygenase assessed as conversion of propranolol to 5-hydroxypropranolol at 5 mM in presence of 5 mM H2O2 and 4 mM ascorbic acid,Other,19394224.0,
473,361719,7,1,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side in human Caco-2 cells at 10 uM,Other,18662878.0,
474,361979,8,1,,103164951,4946,Unspecified,,,,,Membrane permeability by PAMPA,Other,18666771.0,
475,361980,4,3,,103164951,4946,Unspecified,,,,,Membrane permeability assessed as passive transport after 4 hrs by PAMPA,Other,18666771.0,
476,361981,7,1,,103164951,4946,Unspecified,,,,,Membrane permeability by PAMPA in presence of 20% 1-propanol,Other,18666771.0,
477,361982,3,3,,103164951,4946,Unspecified,,,,,Membrane permeability assessed as passive transport after 4 hrs by PAMPA in presence of 20% 1-propanol,Other,18666771.0,
478,361985,3,4,,103164951,4946,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method",Other,18666772.0,
479,361986,3,4,,103164951,4946,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by shake flask method",Other,18666772.0,
480,368064,6,3,,103164951,4946,Unspecified,,,,,Antiarrhythmic activity in anaesthetized iv dosed Wistar rat assessed as decrease in adrenaline-induced cardiac rhythm disturbance administered 15 mins before adrenaline challenge,Other,19131251.0,
481,368076,9,5,,103164951,4946,Active,114754.0,24925.0,9.7,Ki,Displacement of [3H]CGP12177 from beta-1 adrenergic receptor in rat cerebral cortex by liquid scintillation counting,Confirmatory,19131251.0,
482,373867,6,3,,103164951,4946,Unspecified,,,,,Hepatic clearance in human hepatocytes in absence of fetal calf serum,Other,18768239.0,
483,384955,4,4,,103164951,4946,Unspecified,,,,,Intrinsic aqueous solubility at pH 10 by shake-flask method,Other,18396854.0,
484,386623,4,8,,103164951,4946,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
485,386625,9,5,,103164951,4946,Unspecified,313104181.0,6580.0,63.2,IC50,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy,Confirmatory,18788725.0,
486,387875,8,1,,103164951,4946,Unspecified,,,,,Apparent permeability across human Caco-2 cell membrane,Other,18796353.0,
487,394756,3,3,,103164951,4946,Inactive,,,,,Inhibition of [3H]norepinephrine binding to Escherichia coli Qsec by liposome-based scintillation counting assay,Other,18719281.0,
488,395324,3,4,,103164951,4946,Unspecified,,,,,"Lipophilicity, log D at pH 7.4 by liquid chromatography",Other,19256501.0,
489,395325,3,3,,103164951,4946,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
490,395327,3,3,,103164951,4946,Unspecified,,,,,"Dissociation constant, pKa by capillary electrophoresis",Other,19256501.0,
491,395328,3,3,,103164951,4946,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19256501.0,
492,404304,3,10,,103164951,4946,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
493,411793,6,2,,103164951,4946,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein,Other,19108654.0,
494,425652,7,2,,103164951,4946,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
495,425653,7,2,,103164951,4946,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
496,426242,12,2,,103164951,4946,Active,296439450.0,154.0,0.00079,Kd,Binding affinity to human adrenergic beta2 receptor,Confirmatory,19168263.0,
497,432063,8,1,,103164951,4946,Unspecified,,,,,Apparent permeability at pH 7.4 after 24 hrs by PAMPA method,Other,19410338.0,
498,434959,1,1,,85787395,4946,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
499,437168,7,3,,103164951,4946,Unspecified,,,,,Antiarrhythmic activity against adrenaline-induced arrhythmia in iv dosed rat assessed as inhibition of cardiac rhythm disturbance administered 15 mins before adrenaline challenge,Other,19447527.0,
500,438775,7,1,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco-2 cells,Other,19761212.0,
501,438776,7,1,,103164951,4946,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco-2 cells,Other,19761212.0,
502,440293,6,3,,103164951,4946,Unspecified,,,,,"Antiarrhythmic activity in Wistar rat assessed as inhibition of adrenaline-induced premature ventricular beats at 1 mg/kg, iv administered 15 mins before adrenaline challenge measured after 15 mins by electrocardiography",Other,19647907.0,
503,444050,7,1,,103164951,4946,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
504,444051,6,2,,103164951,4946,Unspecified,,,,,Total clearance in human,Other,20070106.0,
505,444052,6,2,,103164951,4946,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
506,444053,6,2,,103164951,4946,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
507,444054,6,1,,103164951,4946,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
508,444055,3,3,,103164951,4946,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
509,444056,3,3,,103164951,4946,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
510,444057,3,3,,103164951,4946,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
511,444058,6,2,,103164951,4946,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
512,451155,3,4,,103164951,4946,Unspecified,,,,,Permeability by PAMPA,Other,19665386.0,
513,455986,3,5,,103164951,4946,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
514,462611,6,1,,103164951,4946,Unspecified,,,,,Effective permeability across artificial membrane at 200 uM by PAMPA using HPLC/MS method,Other,20170117.0,
515,462612,3,3,,103164951,4946,Unspecified,,,,,Permeability across artificial membrane assessed as compound transport at 200 uM after 4 hrs by PAMPA using HPLC/MS method,Other,20170117.0,
516,462613,3,3,,103164951,4946,Unspecified,,,,,Permeability across artificial membrane assessed as membrane retention at 200 uM by PAMPA using HPLC/MS method,Other,20170117.0,
517,462614,6,1,,103164951,4946,Unspecified,,,,,Apparent permeability in BBMEC,Other,20170117.0,
518,462615,3,3,,103164951,4946,Unspecified,,,,,Apparent permeability in BBMEC assessed as compound transport after 2 hrs,Other,20170117.0,
519,462616,3,3,,103164951,4946,Unspecified,,,,,Apparent permeability in BBMEC assessed as membrane retention,Other,20170117.0,
520,463106,1,2,,90341556,4946,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
521,467611,3,6,,103164951,4946,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
522,467612,3,6,,103164951,4946,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
523,467613,5,3,,103164951,4946,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
524,468627,3,4,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side in human Caco-2 cells,Other,19762238.0,
525,468628,3,4,,103164951,4946,Unspecified,,,,,Apparent permeability from basolateral to apical side in human Caco-2 cells,Other,19762238.0,
526,468629,3,4,,103164951,4946,Unspecified,,,,,Ratio of permeability from apical to basolateral side over basolateral to apical side in human Caco-2 cells,Other,19762238.0,
527,476929,3,3,,103164951,4946,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
528,477503,6,1,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side of the human Caco-2 cells at 10 uM after 2 hrs by LC-MS/MS analysis,Other,19786349.0,
529,481439,3,4,,103164951,4946,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
530,481440,3,4,,103164951,4946,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,20373811.0,
531,481441,3,6,,103164951,4946,Unspecified,,,,,Aqueous diffusivity at 37C,Other,20373811.0,
532,481442,3,6,,103164951,4946,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
533,481444,3,4,,103164951,4946,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,20373811.0,
534,481446,5,1,,103164951,4946,Unspecified,,,,,Effective permeability across human jejunum,Other,20373811.0,
535,485290,1,1,,26751802,4946,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
536,485295,1,2,,90341556,4946,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
537,485297,1,1,,90341556,4946,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
538,485298,1,1,,90341556,4946,Inactive,,,11.5821,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
539,485313,1,2,,90341556,4946,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
540,485342,1,2,,90341556,4946,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
541,485345,1,2,,90341556,4946,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
542,485366,1,2,,90341556,4946,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
543,485368,1,2,,90341556,4946,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
544,488772,1,1,,90341556,4946,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
545,488773,1,2,,90341556,4946,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
546,488816,1,1,,90341556,4946,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
547,488837,1,1,,90341556,4946,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
548,488949,1,2,,90341556,4946,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
549,488953,1,1,,90341556,4946,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
550,488978,1,1,,90341556,4946,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
551,488981,1,1,,90341556,4946,Inconclusive,4503383.0,1812.0,14.1254,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
552,488982,1,1,,90341556,4946,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
553,488983,1,1,,90341556,4946,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
554,493106,1,1,,90341556,4946,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
555,493107,1,1,,90341556,4946,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
556,493153,1,1,,90341556,4946,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
557,493153,1,1,,90341556,4946,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
558,493164,1,2,,90341556,4946,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
559,493164,1,2,,90341556,4946,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
560,493164,1,2,,90341556,4946,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
561,496817,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
562,496818,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
563,496819,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
564,496820,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
565,496821,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
566,496823,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
567,496824,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
568,496825,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
569,496826,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
570,496827,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
571,496828,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
572,496829,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
573,496830,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
574,496831,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
575,496832,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
576,497005,4,2,,103164951,4946,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
577,503295,2,6,,103164951,4946,Active,,,,,Inverse agonist activity at beta-2-adrenergic receptor expressed in HEK293 cells assessed as reduction of receptor interaction with beta-arrestin by EYFP based reporter gene assay,Other,16680159.0,
578,503306,2,5,,103164951,4946,Unspecified,,,,,Antiproliferative activity against human PC3 cells at 2 uM after 120 hrs by MTT assay relative to DMSO,Other,16680159.0,
579,504327,1,1,,90341556,4946,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
580,504332,1,1,,90341556,4946,Active,168985070.0,,3.1623,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
581,504536,1,1,,90341556,4946,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
582,504547,1,1,,90341556,4946,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
583,504548,1,2,,90341556,4946,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
584,504810,1,2,,90341556,4946,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
585,504812,1,2,,90341556,4946,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
586,504836,1,2,,90341556,4946,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
587,504845,1,1,,90341556,4946,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
588,504847,1,1,,90341556,4946,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
589,504865,1,1,,90341556,4946,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
590,540209,4,3,,103164951,4946,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
591,540210,4,3,,103164951,4946,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
592,540211,2,5,,103164951,4946,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
593,540212,4,3,,103164951,4946,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
594,540213,4,3,,103164951,4946,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
595,540214,4,3,,103164951,4946,Unspecified,,,,,Clearance in rat after iv administration,Other,15920768.0,
596,540215,3,2,,103164951,4946,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,15920768.0,
597,540216,4,3,,103164951,4946,Unspecified,,,,,Clearance in dog after iv administration,Other,15920768.0,
598,540217,4,3,,103164951,4946,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,15920768.0,
599,540218,4,3,,103164951,4946,Unspecified,,,,,Clearance in monkey after iv administration,Other,15920768.0,
600,540219,4,3,,103164951,4946,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,15920768.0,
601,540220,4,3,,103164951,4946,Unspecified,,,,,Clearance in human after iv administration,Other,15920768.0,
602,540221,4,3,,103164951,4946,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,15920768.0,
603,540230,2,5,,103164951,4946,Unspecified,,,,,Dose normalised AUC in rat after po administration,Other,16019946.0,
604,540231,2,5,,103164951,4946,Unspecified,,,,,Dose normalised AUC in dog after po administration,Other,16019946.0,
605,540232,2,5,,103164951,4946,Unspecified,,,,,Dose normalised AUC in monkey after po administration,Other,16019946.0,
606,540233,2,5,,103164951,4946,Unspecified,,,,,Dose normalised AUC in human after po administration,Other,16019946.0,
607,540234,2,5,,103164951,4946,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
608,540256,1,2,,90341556,4946,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
609,540276,1,2,,26751802,4946,Inconclusive,420597.0,,29.081,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
610,540276,1,2,,50104497,4946,Inconclusive,420597.0,,29.081,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
611,540276,1,2,,90341556,4946,Inconclusive,420597.0,,29.081,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
612,567091,2,6,,103164951,4946,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
613,568395,2,3,,103164951,4946,Unspecified,,,,,"Antihypertensive activity against methyl prednisolone acetate-induced hypertension in albino rat assessed as reduction in mean arterial pressure at 14 mg/kg, ip after 1 hr by tail-cuff method",Other,21211966.0,
614,587815,1,6,,103164951,4946,Unspecified,,,,,Metabolic stability of the compound in human liver microsome assessed as compound remaining,Other,21299244.0,
615,587818,4,1,,103164951,4946,Unspecified,,,,,Apparent permeability across human Caco2 cells,Other,21299244.0,
616,588208,2,3,,103164951,4946,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
617,588209,2,3,,103164951,4946,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
618,588210,2,4,,103164951,4946,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
619,588211,2,3,,103164951,4946,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
620,588212,2,3,,103164951,4946,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
621,588213,2,3,,103164951,4946,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
622,588220,2,3,,103164951,4946,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
623,588349,1,1,,90341556,4946,Inconclusive,,,3.9811,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
624,588378,1,1,,90341556,4946,Inconclusive,171543895.0,6311.0,14.1254,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
625,588453,1,1,,90341556,4946,Inactive,8659577.0,58819.0,39.8107,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
626,588456,1,1,,90341556,4946,Inactive,8659577.0,58819.0,44.6684,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
627,588579,1,1,,90341556,4946,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
628,588579,1,1,,124881056,4946,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
629,588795,1,1,,90341556,4946,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
630,592681,1,4,,103164951,4946,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
631,595744,3,3,,103164951,4946,Unspecified,,,,,Half life in CD1 mouse liver microsomes by LC-MS-MS analysis,Other,21417236.0,
632,595745,3,3,,103164951,4946,Unspecified,,,,,Intrinsic clearance in CD1 mouse liver microsomes by LC-MS-MS analysis,Other,21417236.0,
633,602332,1,1,,90341556,4946,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
634,602332,1,1,,124881056,4946,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
635,603953,1,3,,103164951,4946,Unspecified,,,,,"In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
636,604020,1,4,,103164951,4946,Active,,,,,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
637,604021,3,1,,103164951,4946,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
638,604022,1,4,,103164951,4946,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
639,604023,1,3,,103164951,4946,Unspecified,,,,,Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
640,604024,1,3,,103164951,4946,Unspecified,,,,,Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr,Other,19764786.0,
641,604025,1,4,,103164951,4946,Unspecified,,,,,Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
642,604026,1,4,,103164951,4946,Unspecified,,,,,Unbound CSF to plasma concentration ratio in human,Other,19764786.0,
643,604822,1,4,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side in monkey TC7 cells at 10 umol/L and pH 6.5/7.4,Other,21080703.0,
644,604825,1,6,,103164951,4946,Unspecified,,,,,Metabolic stability in human liver microsomes as compound remaining at 1 uM,Other,21080703.0,
645,604826,1,6,,103164951,4946,Unspecified,,,,,Metabolic stability in mouse liver microsomes as compound remaining at 1 uM,Other,21080703.0,
646,610064,1,4,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM by LC/MS/MS analysis,Other,21764308.0,
647,610065,1,4,,103164951,4946,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM by LC/MS/MS analysis,Other,21764308.0,
648,610066,1,4,,103164951,4946,Unspecified,,,,,Efflux ratio of permeability from basolateral to apical side to apical to basolateral side in human Caco2 cells at 10 uM by LC/MS/MS analysis,Other,21764308.0,
649,620386,4,5,,103164951,4946,Active,48429211.0,153.0,0.00603,Kd,Displacement of [3H]-CGP 12177 from human beta-1 adrenergic receptor expressed in CHOK1 cells,Confirmatory,21870877.0,
650,620387,4,5,,103164951,4946,Active,296439450.0,154.0,0.000603,Kd,Displacement of [3H]-CGP 12177 from human beta-2 adrenergic receptor expressed in CHOK1 cells,Confirmatory,21870877.0,
651,620388,4,5,,103164951,4946,Active,461604.0,155.0,0.2138,Kd,Displacement of [3H]-CGP 12177 from human beta-3 adrenergic receptor expressed in CHOK1 cells,Confirmatory,21870877.0,
652,620389,2,6,,103164951,4946,Active,48429211.0,153.0,0.00182,Kd,Antagonist activity at human beta-1 adrenergic receptor site 1 expressed in cimeterol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,Confirmatory,21870877.0,
653,620390,2,6,,103164951,4946,Active,48429211.0,153.0,0.19952999999999999,Kd,Antagonist activity at human beta-1 adrenergic receptor site 1 expressed in CGP 12177-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,Confirmatory,21870877.0,
654,620391,2,6,,103164951,4946,Active,296439450.0,154.0,0.00023999999999999998,Kd,Antagonist activity at human beta-2 adrenergic receptor expressed in salbutamol-stimulated CHO-K1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,Confirmatory,21870877.0,
655,620392,2,6,,103164951,4946,Active,461604.0,155.0,0.16218,Kd,Antagonist activity at human beta-3 adrenergic receptor expressed in fenoterol-stimulated CHOK1 cells assessed as CRE-SPAP level by fluorescence correlation spectroscopic analysis,Confirmatory,21870877.0,
656,624101,1,2,,85787395,4946,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
657,624146,1,1,,90341556,4946,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
658,624147,1,1,,90341556,4946,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
659,624148,1,2,,90341556,4946,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
660,624149,1,1,,90341556,4946,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
661,624151,1,1,,85787395,4946,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
662,624156,1,1,,85787395,4946,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
663,624349,1,2,,92309237,4946,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
664,624455,1,1,,90341556,4946,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
665,624606,1,9,,103164951,4946,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
666,624611,1,9,,103164951,4946,Unspecified,29839637.0,54576.0,,,Specific activity of expressed human recombinant UGT1A8,Other,10836148.0,
667,624612,1,9,,103164951,4946,Unspecified,29839451.0,54600.0,,,Specific activity of expressed human recombinant UGT1A9,Other,10836148.0,
668,624613,1,9,,103164951,4946,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
669,624615,1,8,,103164951,4946,Unspecified,549155.0,7365.0,,,Specific activity of expressed human recombinant UGT2B10,Other,10836148.0,
670,624618,3,2,,103164951,4946,Unspecified,6175083.0,7363.0,,,Specific activity of expressed human recombinant UGT2B4,Other,10836148.0,
671,624619,3,2,,103164951,4946,Unspecified,136727.0,7364.0,,,Specific activity of expressed human recombinant UGT2B7,Other,10836148.0,
672,624622,3,1,,103164951,4946,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
673,624623,3,1,,103164951,4946,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
674,624624,3,1,,103164951,4946,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells in the presence of inhibitor (2uM GF120919),Other,11602674.0,
675,624625,3,1,,103164951,4946,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells in the presence of inhibitor (2uM GF120919),Other,11602674.0,
676,624626,1,9,,103164951,4946,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
677,624627,1,9,,103164951,4946,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells in the presence of inhibitor (2uM GF120919),Other,11602674.0,
678,624628,1,9,,103164951,4946,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
679,624629,1,9,,103164951,4946,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
680,625144,5,5,,103164951,4946,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
681,625145,4,7,,103164951,4946,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
682,625146,5,5,,103164951,4946,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
683,625147,4,7,,103164951,4946,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
684,625148,4,7,,103164951,4946,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
685,625149,4,7,,103164951,4946,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
686,625150,5,5,,103164951,4946,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
687,625151,4,7,,103164951,4946,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
688,625152,4,7,,103164951,4946,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
689,625153,4,7,,103164951,4946,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
690,625154,4,7,,103164951,4946,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
691,625155,4,7,,103164951,4946,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
692,625156,1,9,,103164951,4946,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
693,625157,6,2,,103164951,4946,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
694,625158,3,4,,103164951,4946,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
695,625159,5,5,,103164951,4946,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
696,625160,1,9,,103164951,4946,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
697,625161,4,7,,103164951,4946,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
698,625162,4,7,,103164951,4946,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
699,625163,4,7,,103164951,4946,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
700,625164,1,6,,103164951,4946,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
701,625165,3,4,,103164951,4946,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
702,625166,3,4,,103164951,4946,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
703,625167,5,5,,103164951,4946,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
704,625168,4,7,,103164951,4946,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
705,625169,1,6,,103164951,4946,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
706,625170,3,4,,103164951,4946,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
707,625171,4,7,,103164951,4946,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
708,625172,4,7,,103164951,4946,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
709,625173,5,5,,103164951,4946,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
710,625174,5,5,,103164951,4946,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
711,625175,5,5,,103164951,4946,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
712,625176,1,9,,103164951,4946,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
713,625177,5,5,,103164951,4946,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
714,625178,5,5,,103164951,4946,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
715,625179,1,9,,103164951,4946,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
716,625180,5,5,,103164951,4946,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
717,625181,5,5,,103164951,4946,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
718,625182,5,5,,103164951,4946,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
719,625183,5,5,,103164951,4946,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
720,625184,5,5,,103164951,4946,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
721,625185,5,5,,103164951,4946,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
722,625186,5,5,,103164951,4946,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
723,625187,5,5,,103164951,4946,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
724,625188,1,9,,103164951,4946,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
725,625189,1,7,,103164951,4946,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
726,625190,4,5,,103164951,4946,Active,,,0.243,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
727,625191,4,7,,103164951,4946,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
728,625192,4,7,,103164951,4946,Active,543727.0,3356.0,1.466,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
729,625193,5,5,,103164951,4946,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
730,625194,4,7,,103164951,4946,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
731,625195,4,7,,103164951,4946,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
732,625196,5,6,,103164951,4946,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
733,625197,3,4,,103164951,4946,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
734,625198,4,7,,103164951,4946,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
735,625199,4,7,,103164951,4946,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
736,625200,4,7,,103164951,4946,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
737,625201,4,7,,103164951,4946,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
738,625202,4,7,,103164951,4946,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
739,625203,4,7,,103164951,4946,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
740,625204,4,7,,103164951,4946,Active,48429211.0,153.0,0.0025399999999999997,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
741,625205,4,7,,103164951,4946,Active,296439450.0,154.0,0.00112,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
742,625206,4,7,,103164951,4946,Active,461604.0,155.0,0.132,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
743,625207,4,7,,103164951,4946,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
744,625208,5,5,,103164951,4946,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
745,625209,4,7,,103164951,4946,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
746,625210,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
747,625211,1,6,,103164951,4946,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
748,625212,3,4,,103164951,4946,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
749,625213,4,7,,103164951,4946,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
750,625214,1,9,,103164951,4946,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
751,625215,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
752,625216,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
753,625217,4,7,,103164951,4946,Active,1168220.0,3357.0,0.342,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
754,625218,4,7,,103164951,4946,Active,112816.0,3358.0,2.294,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
755,625219,3,4,,103164951,4946,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
756,625220,4,7,,103164951,4946,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
757,625221,4,7,,103164951,4946,Active,1703010.0,3362.0,3.065,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
758,625222,4,7,,103164951,4946,Active,400630.0,6532.0,0.38,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
759,625223,4,7,,103164951,4946,Active,74752153.0,10280.0,2.87,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
760,625224,3,4,,103164951,4946,Active,,,3.467,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
761,625225,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
762,625226,4,7,,103164951,4946,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
763,625227,4,7,,103164951,4946,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
764,625228,4,7,,103164951,4946,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
765,625229,5,5,,103164951,4946,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
766,625230,1,6,,103164951,4946,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
767,625231,4,7,,103164951,4946,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
768,625232,1,9,,103164951,4946,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
769,625233,4,7,,103164951,4946,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
770,625234,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
771,625235,4,7,,103164951,4946,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
772,625236,5,5,,103164951,4946,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
773,625237,4,7,,103164951,4946,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
774,625238,4,7,,103164951,4946,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
775,625239,4,7,,103164951,4946,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
776,625240,1,9,,103164951,4946,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
777,625241,4,7,,103164951,4946,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
778,625242,4,7,,103164951,4946,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
779,625243,5,5,,103164951,4946,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
780,625244,5,5,,103164951,4946,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
781,625245,5,5,,103164951,4946,Active,117144.0,1544.0,4.0,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
782,625246,1,9,,103164951,4946,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
783,625247,5,5,,103164951,4946,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
784,625248,5,5,,103164951,4946,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
785,625249,5,5,,103164951,4946,Active,84028191.0,1565.0,2.0,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
786,625250,5,5,,103164951,4946,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
787,625251,5,5,,103164951,4946,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
788,625252,4,7,,103164951,4946,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
789,625253,4,7,,103164951,4946,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
790,625254,4,7,,103164951,4946,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
791,625255,4,7,,103164951,4946,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
792,625256,4,7,,103164951,4946,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
793,625257,4,7,,103164951,4946,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
794,625258,4,7,,103164951,4946,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
795,625259,4,7,,103164951,4946,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
796,625260,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
797,625261,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
798,625262,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
799,625263,4,7,,103164951,4946,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
800,625264,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
801,625265,1,6,,103164951,4946,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
802,625266,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
803,625267,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
804,625268,4,2,,103164951,4946,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
805,625268,4,2,,103164951,4946,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
806,625268,4,2,,103164951,4946,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
807,625268,4,2,,103164951,4946,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
808,625269,4,7,,103164951,4946,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
809,625270,4,7,,103164951,4946,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
810,625271,5,5,,103164951,4946,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
811,625272,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
812,625273,4,6,,103164951,4946,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
813,625274,1,6,,103164951,4946,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
814,625275,3,4,,103164951,4946,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
815,625277,1,3,,103164951,4946,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
816,625279,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
817,625280,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
818,625281,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
819,625282,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
820,625283,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
821,625284,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
822,625285,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
823,625286,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
824,625287,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
825,625288,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
826,625289,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
827,625290,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
828,625291,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
829,625292,1,3,,103164951,4946,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
830,636075,3,4,,103164951,4946,Active,,,37.68,IC50,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D10 after 48 hrs by lactate dehydrogenase assay,Confirmatory,22196513.0,
831,636076,3,2,,103164951,4946,Active,,,10.19,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs by lactate dehydrogenase assay,Confirmatory,22196513.0,
832,636077,1,4,,103164951,4946,Unspecified,,,,,"Resistance index, ratio of IC50 for chloroquine-resistant Plasmodium falciparum K1 to IC50 for chloroquine-sensitive Plasmodium falciparum D10",Other,22196513.0,
833,636078,3,2,,103164951,4946,Unspecified,,,300.0,IC50,Cytotoxicity against CHO cells after 48 hrs by MTT assay,Confirmatory,22196513.0,
834,636084,1,4,,103164951,4946,Unspecified,,,,,Antiplasmodial activity against Plasmodium falciparum schizonts assessed as parasitemia at IC50 concentration treated until all schizonts had burst and invasion was assumed to have occurred by Giemsa staining-based microscopy (Rvb = 8.83%),Other,22196513.0,
835,636085,1,4,,103164951,4946,Unspecified,,,,,Antiplasmodial activity against Plasmodium falciparum schizonts assessed as change in parasitemia at IC50 concentration treated until all schizonts had burst and invasion was assumed to have occurred by Giemsa staining-based microscopy relative to control,Other,22196513.0,
836,642115,1,6,,103164951,4946,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as compound remaining after 30 mins by LC-MS/MS analysis,Other,22044164.0,
837,642116,1,5,,103164951,4946,Unspecified,,,,,Metabolic stability in mouse liver microsomes assessed as compound remaining after 30 mins by LC-Ms/Ms analysis,Other,22044164.0,
838,643279,3,3,,103164951,4946,Unspecified,,,,,Half life in CD-1 mouse liver microsomes at 1 uM by LC-MS/MS analysis,Other,22098589.0,
839,643280,3,3,,103164951,4946,Unspecified,,,,,Intrinsic clearance in CD-1 mouse liver microsomes at 1 uM by LC-MS/MS analysis,Other,22098589.0,
840,643383,1,6,,103164951,4946,Unspecified,,,,,Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy,Other,22122484.0,
841,651635,1,3,,90341556,4946,Inconclusive,171543895.0,6311.0,22.3872,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
842,651741,1,1,,124881057,4946,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
843,651828,1,2,,92309237,4946,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
844,652106,1,1,,90341556,4946,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
845,658930,1,3,,103164951,4946,Unspecified,,,,,Influx ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells at 100 uM up to 90 mins,Other,22464423.0,
846,658932,1,3,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 100 uM up to 90 mins,Other,22464423.0,
847,658937,1,3,,103164951,4946,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 100 uM up to 90 mins,Other,22464423.0,
848,658938,1,3,,103164951,4946,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side in human Caco2 cells at 100 uM up to 90 mins,Other,22464423.0,
849,666534,1,4,,103164951,4946,Active,,,,,Antiarrhythmic activity in iv dosed Wistar rat assessed as protection against adrenaline-induced extrasystoles administered 15 mins prior to adrenaline-challenge,Other,22381672.0,
850,666535,1,4,,103164951,4946,Active,,,,,Antiarrhythmic activity in iv dosed Wistar rat assessed as protection against adrenaline-induced bigeminy administered 15 mins prior to adrenaline-challenge,Other,22381672.0,
851,666536,1,4,,103164951,4946,Active,,,,,Antiarrhythmic activity in iv dosed adrenaline-induced Wistar rat arrhythmia model assessed as protection against mortality administered 15 mins prior to barium chloride-challenge,Other,22381672.0,
852,666540,2,3,,103164951,4946,Unspecified,,,,,Antiarrhythmic activity in iv dosed Wistar rat assessed as protection against adrenaline-induced arrhythmia administered 15 mins prior to adrenaline-challenge,Other,22381672.0,
853,678712,1,8,,103164951,4946,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
854,678713,1,8,,103164951,4946,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
855,678714,1,8,,103164951,4946,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
856,678715,1,8,,103164951,4946,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
857,678716,1,8,,103164951,4946,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
858,678717,1,8,,103164951,4946,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
859,678721,1,5,,103164951,4946,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
860,678722,1,5,,103164951,4946,Unspecified,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
861,679346,1,8,,103164951,4946,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in Caco2 cells,Other,15023456.0,
862,679499,2,7,,103164951,4946,Unspecified,313104182.0,6582.0,,Km,TP_TRANSPORTER: uptake in OCT2-expressing mIMCD3 cells,Confirmatory,10960071.0,
863,680283,1,8,,103164951,4946,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Propranolol: 500 uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
864,681378,3,6,,103164951,4946,Unspecified,2498046.0,6554.0,5.5,IC50,TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells,Confirmatory,10565843.0,
865,681961,1,7,,103164951,4946,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of cimetidine uptake (Cimetidine: 100 uM, Propranolol: 1000 uM) in OCT2-expressing mIMCD3 cells",Other,10960071.0,
866,686977,2,1,,49698887,4946,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
867,686978,1,1,,124881056,4946,Active,79154014.0,55775.0,16.3601,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
868,686979,1,1,,124881056,4946,Active,79154014.0,55775.0,16.3601,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
869,694016,3,1,,103164951,4946,Unspecified,,,,,Permeability across MDCK2-MDR1 cells expressing MDR1 at 3 uM in presence of 2 uM P-gp inhibitor Elacridal by mass spectroscopy,Other,22720744.0,
870,694133,1,4,,103164951,4946,Unspecified,,,,,Binding affinity to MDR1 expressed in MDCK2 cells assessed as absorptive quotient at at 3 uM in absence of 2 uM by mass spectroscopy,Other,22720744.0,
871,695707,3,1,,103164951,4946,Unspecified,,,,,Apparent permeability across human Caco2 cells at 200 uM by LC/MS analysis,Other,22680612.0,
872,695938,3,1,,103164951,4946,Unspecified,,,,,Apparent permeability across human Caco2 cells st 200 uM measured over 150 mins by LC/MS analysis,Other,23022277.0,
873,699539,1,7,,103164951,4946,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
874,699540,1,7,,103164951,4946,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
875,699541,1,7,,103164951,4946,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
876,702960,2,5,,103164951,4946,Unspecified,,,,,Half life in human liver microsomes,Other,22712432.0,
877,702961,2,5,,103164951,4946,Unspecified,,,,,Intrinsic clearance in human liver microsomes,Other,22712432.0,
878,702975,2,3,,103164951,4946,Unspecified,,,,,Clearance in human hepatocytes in the presence of fetal calf serum,Other,22712432.0,
879,718837,1,2,,103164951,4946,Unspecified,,,,,Permeability of the compound by PAMPA,Other,23102654.0,
880,720532,1,1,,124881056,4946,Inconclusive,420597.0,,22.3872,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
881,720533,1,1,,124881056,4946,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
882,720538,1,2,,90341556,4946,Inactive,220983390.0,410.0,2.1331,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
883,720559,1,2,,90341556,4946,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
884,720572,1,2,,90341556,4946,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
885,720573,1,2,,90341556,4946,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
886,720579,2,1,,124881056,4946,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
887,720580,1,1,,124881056,4946,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
888,720636,1,1,,124881057,4946,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
889,720641,1,2,,92309237,4946,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
890,720717,1,3,,92309237,4946,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
891,721850,1,3,,103164951,4946,Unspecified,,,,,Metabolic stability in mouse liver microsomes assessed as compound remaining after 30 mins by LC-MS/MS assay,Other,23214452.0,
892,721851,1,4,,103164951,4946,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as compound remaining after 30 mins by LC-MS/MS assay,Other,23214452.0,
893,722794,1,3,,103164951,4946,Unspecified,,,,,Antiarrhythmic activity in iv dosed Wistar rat adrenaline-induced arrhythmia model assessed as reduction of heart-rhythm disturbance administered 15 mins adrenaline-challenge,Other,23245804.0,
894,730927,3,1,,103164951,4946,Unspecified,,,,,Permeability of the compound at pH 7.4 by PAMPA,Other,23167526.0,
895,737301,3,1,,103164951,4946,Unspecified,,,,,Permeability of the compound,Other,23454015.0,
896,737835,1,2,,103164951,4946,Inactive,,,,,Antiangiogenic activity in human HMEC1 cells at 10 uM after 8 hrs by matrigel assay,Other,23462711.0,
897,737836,1,2,,103164951,4946,Unspecified,,,,,Selectivity ratio of GI50 for human MRC5 cells to GI50 for human MDA-MB-231 cells,Other,23462711.0,
898,737837,1,2,,103164951,4946,Unspecified,,,,,Selectivity ratio of GI50 for human MRC5 cells to GI50 for human SHEP cells,Other,23462711.0,
899,737838,1,2,,103164951,4946,Unspecified,,,,,Selectivity ratio of GI50 for human MRC5 cells to GI50 for human HMEC1 cells,Other,23462711.0,
900,737839,1,2,,103164951,4946,Unspecified,,,150.0,GI50,Antiproliferative activity against human MRC5 cells by measuring metabolic activity of cells after 72 hrs by spectrophotometric analysis,Confirmatory,23462711.0,
901,737840,1,3,,103164951,4946,Unspecified,,,109.0,GI50,Antiproliferative activity against human SHEP cells by measuring metabolic activity of cells after 72 hrs by spectrophotometric analysis,Confirmatory,23462711.0,
902,737841,1,2,,103164951,4946,Unspecified,,,205.0,GI50,Antiproliferative activity against human MDA-MB-231 cells by measuring metabolic activity of cells after 72 hrs by spectrophotometric analysis,Confirmatory,23462711.0,
903,737842,1,3,,103164951,4946,Unspecified,,,149.0,GI50,Antiproliferative activity against human HMEC1 cells by measuring metabolic activity of cells after 72 hrs by spectrophotometric analysis,Confirmatory,23462711.0,
904,743205,1,1,,90341556,4946,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
905,743205,1,1,,90341556,4946,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
906,743206,1,1,,90341556,4946,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
907,743206,1,1,,90341556,4946,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
908,743207,1,1,,90341556,4946,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
909,743207,1,1,,90341556,4946,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
910,743244,1,1,,90341556,4946,Inconclusive,,,5.6234,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
911,744880,1,2,,103164951,4946,Unspecified,,,,,"Toxicity in rat spontaneous hypertensive model assessed as heart rate at 20 mg/kg, po measured at 8 hrs by tail-cuff method (Rvb = 397.2 +/- 24.87 bpm)",Other,23538234.0,
912,744882,1,2,,103164951,4946,Unspecified,,,,,"Toxicity in rat spontaneous hypertensive model assessed as heart rate at 20 mg/kg, po measured at 6 hrs by tail-cuff method (Rvb = 405.1 +/- 24 bpm)",Other,23538234.0,
913,744884,1,2,,103164951,4946,Unspecified,,,,,"Toxicity in rat spontaneous hypertensive model assessed as heart rate at 20 mg/kg, po measured at 4 hrs by tail-cuff method (Rvb = 403.1 +/- 15.92 bpm)",Other,23538234.0,
914,744886,1,2,,103164951,4946,Unspecified,,,,,"Toxicity in rat spontaneous hypertensive model assessed as heart rate at 20 mg/kg, po measured at 2 hrs by tail-cuff method (Rvb = 399.5 +/- 19.68 bpm)",Other,23538234.0,
915,744888,1,2,,103164951,4946,Unspecified,,,,,"Toxicity in rat spontaneous hypertensive model assessed as heart rate at 20 mg/kg, po measured at 1 hr by tail-cuff method (Rvb = 403.9 +/- 12.41 bpm)",Other,23538234.0,
916,744890,1,2,,103164951,4946,Unspecified,,,,,"Toxicity in rat spontaneous hypertensive model assessed as heart rate at 20 mg/kg, po measured at 0.5 hrs by tail-cuff method (Rvb = 406.5 +/- 13.15 bpm)",Other,23538234.0,
917,744892,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as mean arterial blood pressure at 20 mg/kg, po measured at 8 hrs by tail-cuff method (Rvb = 155.8 +/- 11.54 mmHg)",Other,23538234.0,
918,744894,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as mean arterial blood pressure at 20 mg/kg, po measured at 6 hrs by tail-cuff method (Rvb = 155.8 +/- 7.97 mmHg)",Other,23538234.0,
919,744896,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as mean arterial blood pressure at 20 mg/kg, po measured at 4 hrs by tail-cuff method (Rvb = 154.4 +/- 20.1 mmHg)",Other,23538234.0,
920,744898,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as mean arterial blood pressure at 20 mg/kg, po measured at 2 hrs by tail-cuff method (Rvb = 157.41 +/- 9.62 mmHg)",Other,23538234.0,
921,744900,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as mean arterial blood pressure at 20 mg/kg, po measured at 1 hr by tail-cuff method (Rvb = 158.9 +/- 13.65 mmHg)",Other,23538234.0,
922,744902,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as mean arterial blood pressure at 20 mg/kg, po measured at 0.5 hrs by tail-cuff method (Rvb = 156.2 +/- 7.21 mmHg)",Other,23538234.0,
923,744904,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as diastolic arterial blood pressure at 20 mg/kg, po measured at 8 hrs by tail-cuff method (Rvb = 135.3 +/- 8.21 mmHg)",Other,23538234.0,
924,744906,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as diastolic arterial blood pressure at 20 mg/kg, po measured at 6 hrs by tail-cuff method (Rvb = 141.2 +/- 7.34 mmHg)",Other,23538234.0,
925,744908,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as diastolic arterial blood pressure at 20 mg/kg, po measured at 4 hrs by tail-cuff method (Rvb = 141.4 +/- 7.11 mmHg)",Other,23538234.0,
926,744910,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as diastolic arterial blood pressure at 20 mg/kg, po measured at 2 hrs by tail-cuff method (Rvb = 142.9 +/- 18.07 mmHg)",Other,23538234.0,
927,744912,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as diastolic arterial blood pressure at 20 mg/kg, po measured at 1 hr by tail-cuff method (Rvb = 146.2 +/- 13.19 mmHg)",Other,23538234.0,
928,744914,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as diastolic arterial blood pressure at 20 mg/kg, po measured at 0.5 hrs by tail-cuff method (Rvb = 138.7 +/- 9.2 mmHg)",Other,23538234.0,
929,744916,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as systolic arterial blood pressure at 20 mg/kg, po measured at 8 hrs by tail-cuff method (Rvb = 174 +/- 12.1 mmHg)",Other,23538234.0,
930,744918,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as systolic arterial blood pressure at 20 mg/kg, po measured at 6 hrs by tail-cuff method (Rvb = 176.7 +/- 15.21 mmHg)",Other,23538234.0,
931,744920,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as systolic arterial blood pressure at 20 mg/kg, po measured at 4 hrs by tail-cuff method (Rvb = 172.9 +/- 10.21 mmHg)",Other,23538234.0,
932,744922,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as systolic arterial blood pressure at 20 mg/kg, po measured at 2 hrs by tail-cuff method (Rvb = 172.6 +/- 17.3 mmHg)",Other,23538234.0,
933,744924,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as systolic arterial blood pressure at 20 mg/kg, po measured at 1 hr by tail-cuff method (Rvb = 181.2 +/- 16.37 mmHg)",Other,23538234.0,
934,744926,1,2,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in rat spontaneous hypertensive model assessed as systolic arterial blood pressure at 20 mg/kg, po measured at 0.5 hrs by tail-cuff method (Rvb = 178.5 +/- 10.13 mmHg)",Other,23538234.0,
935,744927,1,5,,103164951,4946,Unspecified,114754.0,24925.0,,,Antagonist activity at beta1 adrenoreceptor in Sprague-Dawley rat left atrium assessed as inhibition of isoprenaline-induced contraction at 1 uM incubated for 5 mins prior to isoprenaline-induction,Other,23538234.0,
936,744928,1,5,,103164951,4946,Unspecified,114754.0,24925.0,,,Antagonist activity at beta1 adrenoreceptor in Sprague-Dawley rat left atrium assessed as inhibition of isoprenaline-induced contraction at 0.1 uM incubated for 5 mins prior to isoprenaline-induction,Other,23538234.0,
937,755839,1,1,,103164951,4946,Unspecified,,,,,Oral bioavailability in rat,Other,23713656.0,
938,755840,2,1,,103164951,4946,Unspecified,,,,,Passive permebility in wild-type MDCK cells,Other,23713656.0,
939,759362,1,1,,103164951,4946,Active,,,0.006999999999999999,Ki,Displacement of [3H]CGP-12177 from beta1-adrenergic receptor in rat cerebral cortex after 60 mins by scintillation counting,Confirmatory,23787101.0,
940,765484,1,3,,103164951,4946,Unspecified,,,,,Half life in human liver microsomes at 1 uM by LC-MS analysis,Other,23867604.0,
941,771851,1,3,,103164951,4946,Unspecified,,,,,Antihypertensive activity in rat assessed as inhibition of isoproterenol-induced tachycardia,Other,,
942,772976,1,3,,103164951,4946,Unspecified,,,,,Half life in human liver microsomes at 1 uM after 1 to 60 mins by UHPLC-MS/MS analysis,Other,23994869.0,
943,781326,1,2,,103164951,4946,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
944,781328,1,2,,103164951,4946,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
945,909151,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/5,Other,,
946,909152,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/5,Other,,
947,909153,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/5,Other,,
948,909154,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/5,Other,,
949,909155,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/5,Other,,
950,909156,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/5,Other,,
951,909157,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/5,Other,,
952,909158,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/5,Other,,
953,909159,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/5,Other,,
954,909160,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/5,Other,,
955,909161,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/5,Other,,
956,909162,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/5,Other,,
957,909163,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/5,Other,,
958,909164,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/5,Other,,
959,909165,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/6,Other,,
960,909166,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/6,Other,,
961,909167,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/6,Other,,
962,909168,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/6,Other,,
963,909169,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/6,Other,,
964,909170,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/6,Other,,
965,909171,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/6,Other,,
966,909172,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/6,Other,,
967,909173,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/6,Other,,
968,909174,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/6,Other,,
969,909175,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/6,Other,,
970,909176,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/6,Other,,
971,909177,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/6,Other,,
972,909178,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/6,Other,,
973,909179,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/6,Other,,
974,909180,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/6,Other,,
975,909181,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/6,Other,,
976,909182,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/6,Other,,
977,909183,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/6,Other,,
978,909184,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/7,Other,,
979,909185,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/7,Other,,
980,909186,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/7,Other,,
981,909187,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/7,Other,,
982,909188,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/7,Other,,
983,909189,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/7,Other,,
984,909190,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/7,Other,,
985,909191,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/7,Other,,
986,909192,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/7,Other,,
987,909193,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/7,Other,,
988,909194,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/7,Other,,
989,909195,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/7,Other,,
990,909196,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/7,Other,,
991,909197,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/15,Other,,
992,909198,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/15,Other,,
993,909199,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/15,Other,,
994,909200,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/15,Other,,
995,909201,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/15,Other,,
996,909202,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/15,Other,,
997,909203,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/15,Other,,
998,909204,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/15,Other,,
999,909205,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/15,Other,,
1000,909206,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/15,Other,,
1001,909207,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/15,Other,,
1002,909208,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/15,Other,,
1003,909209,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/16,Other,,
1004,909210,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/16,Other,,
1005,909211,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/16,Other,,
1006,909212,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/16,Other,,
1007,909213,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/16,Other,,
1008,909230,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/13,Other,,
1009,909231,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/13,Other,,
1010,909232,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/13,Other,,
1011,909233,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/13,Other,,
1012,909234,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/13,Other,,
1013,909235,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/13,Other,,
1014,909236,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/13,Other,,
1015,909237,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/13,Other,,
1016,909238,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/13,Other,,
1017,909239,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/13,Other,,
1018,909240,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/13,Other,,
1019,909241,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/13,Other,,
1020,909242,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/13,Other,,
1021,909243,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/14,Other,,
1022,909244,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/14,Other,,
1023,909245,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/14,Other,,
1024,909246,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/14,Other,,
1025,909247,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/14,Other,,
1026,909248,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/14,Other,,
1027,909249,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/14,Other,,
1028,909250,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/14,Other,,
1029,909251,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/14,Other,,
1030,909252,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/14,Other,,
1031,909253,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/14,Other,,
1032,909254,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/14,Other,,
1033,909255,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/14,Other,,
1034,909256,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/14,Other,,
1035,909257,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/14,Other,,
1036,909258,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/14,Other,,
1037,909627,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/7,Other,,
1038,909628,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/7,Other,,
1039,909673,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/16,Other,,
1040,909674,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/16,Other,,
1041,909675,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/16,Other,,
1042,909676,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/16,Other,,
1043,909677,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/16,Other,,
1044,909678,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/16,Other,,
1045,909679,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/16,Other,,
1046,909680,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/16,Other,,
1047,909681,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/16,Other,,
1048,909682,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/16,Other,,
1049,909683,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/16,Other,,
1050,909684,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/16,Other,,
1051,909685,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/16,Other,,
1052,909686,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/16,Other,,
1053,909687,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/5,Other,,
1054,909688,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/5,Other,,
1055,909689,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/5,Other,,
1056,909690,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/5,Other,,
1057,909691,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/5,Other,,
1058,909692,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/5,Other,,
1059,909693,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/5,Other,,
1060,909694,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/5,Other,,
1061,909695,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/5,Other,,
1062,909696,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/5,Other,,
1063,909697,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/5,Other,,
1064,909698,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/5,Other,,
1065,909699,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/5,Other,,
1066,909700,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/5,Other,,
1067,909701,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/5,Other,,
1068,909702,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/5,Other,,
1069,909703,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/5,Other,,
1070,909719,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/14,Other,,
1071,909720,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/14,Other,,
1072,909721,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/14,Other,,
1073,909722,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/15,Other,,
1074,909723,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/15,Other,,
1075,909724,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/15,Other,,
1076,909725,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/15,Other,,
1077,909726,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/15,Other,,
1078,909727,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/15,Other,,
1079,909728,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/15,Other,,
1080,909729,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/15,Other,,
1081,909730,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/15,Other,,
1082,909731,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/15,Other,,
1083,909732,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/15,Other,,
1084,909733,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/15,Other,,
1085,909734,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/15,Other,,
1086,909735,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/15,Other,,
1087,909736,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/15,Other,,
1088,910973,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/7,Other,,
1089,910974,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/7,Other,,
1090,910975,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/7,Other,,
1091,910976,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/7,Other,,
1092,910977,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/8,Other,,
1093,910978,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/8,Other,,
1094,910979,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/8,Other,,
1095,910980,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/8,Other,,
1096,910981,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/8,Other,,
1097,910982,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/8,Other,,
1098,910983,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/8,Other,,
1099,910984,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/8,Other,,
1100,910985,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/8,Other,,
1101,910986,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/8,Other,,
1102,910987,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/8,Other,,
1103,910988,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/8,Other,,
1104,910989,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/8,Other,,
1105,910990,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/8,Other,,
1106,910991,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/8,Other,,
1107,910992,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/8,Other,,
1108,910993,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/8,Other,,
1109,910994,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/8,Other,,
1110,910995,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/8,Other,,
1111,910996,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/9,Other,,
1112,910997,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/9,Other,,
1113,910998,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/9,Other,,
1114,910999,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/9,Other,,
1115,911000,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/9,Other,,
1116,911001,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/9,Other,,
1117,911002,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/9,Other,,
1118,911003,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/9,Other,,
1119,911004,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/9,Other,,
1120,911005,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/9,Other,,
1121,911006,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/9,Other,,
1122,911007,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/9,Other,,
1123,911008,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/9,Other,,
1124,911009,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/9,Other,,
1125,911010,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/9,Other,,
1126,911011,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/5,Other,,
1127,911012,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/5,Other,,
1128,911013,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/6,Other,,
1129,911014,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/6,Other,,
1130,911015,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/6,Other,,
1131,911016,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/6,Other,,
1132,911017,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/6,Other,,
1133,911018,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/6,Other,,
1134,911019,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/6,Other,,
1135,911044,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/15,Other,,
1136,911045,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/15,Other,,
1137,911046,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/15,Other,,
1138,911047,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/15,Other,,
1139,911048,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/16,Other,,
1140,911049,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/16,Other,,
1141,911050,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/16,Other,,
1142,911051,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/16,Other,,
1143,911052,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/16,Other,,
1144,911053,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/16,Other,,
1145,911054,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/16,Other,,
1146,911055,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/16,Other,,
1147,911056,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/16,Other,,
1148,911057,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/16,Other,,
1149,911058,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/16,Other,,
1150,911059,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/16,Other,,
1151,911060,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/16,Other,,
1152,911061,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/16,Other,,
1153,911062,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/16,Other,,
1154,911063,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/16,Other,,
1155,911064,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/16,Other,,
1156,911442,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/9,Other,,
1157,911443,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/9,Other,,
1158,911444,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/9,Other,,
1159,911445,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/10,Other,,
1160,911446,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/10,Other,,
1161,911447,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/10,Other,,
1162,911448,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/10,Other,,
1163,911449,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/10,Other,,
1164,911450,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/10,Other,,
1165,911484,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/9,Other,,
1166,911488,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/6,Other,,
1167,911489,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/6,Other,,
1168,911490,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/6,Other,,
1169,911491,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/6,Other,,
1170,911492,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/6,Other,,
1171,911493,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/6,Other,,
1172,911494,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/6,Other,,
1173,911495,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/6,Other,,
1174,911496,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/6,Other,,
1175,911497,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/6,Other,,
1176,911498,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/6,Other,,
1177,911499,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/6,Other,,
1178,911500,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/7,Other,,
1179,911501,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/7,Other,,
1180,911502,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/7,Other,,
1181,911503,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/7,Other,,
1182,911504,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/7,Other,,
1183,911505,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/7,Other,,
1184,911506,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/7,Other,,
1185,911507,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/7,Other,,
1186,911508,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/7,Other,,
1187,911509,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/7,Other,,
1188,911510,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/7,Other,,
1189,911511,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/7,Other,,
1190,911512,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/7,Other,,
1191,911513,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/7,Other,,
1192,911514,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/7,Other,,
1193,911515,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/7,Other,,
1194,911516,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/7,Other,,
1195,911517,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/7,Other,,
1196,911518,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/7,Other,,
1197,911519,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/8,Other,,
1198,911520,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/8,Other,,
1199,911521,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/8,Other,,
1200,911522,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/8,Other,,
1201,911523,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/8,Other,,
1202,911524,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/8,Other,,
1203,911525,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/8,Other,,
1204,911533,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/16,Other,,
1205,911534,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/16,Other,,
1206,912836,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/10,Other,,
1207,912837,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/10,Other,,
1208,912838,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/10,Other,,
1209,912839,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/10,Other,,
1210,912840,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/10,Other,,
1211,912841,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/10,Other,,
1212,912842,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/10,Other,,
1213,912843,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/10,Other,,
1214,912844,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/10,Other,,
1215,912845,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/10,Other,,
1216,912846,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/10,Other,,
1217,912847,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/10,Other,,
1218,912848,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/10,Other,,
1219,912849,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/11,Other,,
1220,912850,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/11,Other,,
1221,912851,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/11,Other,,
1222,912852,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/11,Other,,
1223,912853,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/11,Other,,
1224,912854,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/11,Other,,
1225,912855,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/11,Other,,
1226,912856,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/11,Other,,
1227,912857,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/11,Other,,
1228,912858,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/11,Other,,
1229,912859,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/11,Other,,
1230,912860,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/11,Other,,
1231,912861,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/11,Other,,
1232,912862,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/11,Other,,
1233,912863,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/11,Other,,
1234,912864,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/11,Other,,
1235,912865,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/11,Other,,
1236,912911,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/8,Other,,
1237,913296,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/11,Other,,
1238,913297,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/11,Other,,
1239,913298,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/12,Other,,
1240,913299,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/12,Other,,
1241,913300,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/12,Other,,
1242,913301,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/12,Other,,
1243,913302,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/12,Other,,
1244,913303,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/12,Other,,
1245,913304,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/12,Other,,
1246,913305,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/12,Other,,
1247,913306,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/12,Other,,
1248,913307,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/12,Other,,
1249,913308,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/12,Other,,
1250,913309,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/12,Other,,
1251,913310,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/12,Other,,
1252,913311,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/12,Other,,
1253,913312,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/12,Other,,
1254,913313,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/12,Other,,
1255,913342,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/8,Other,,
1256,913343,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/8,Other,,
1257,913344,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/8,Other,,
1258,913345,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/8,Other,,
1259,913346,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/8,Other,,
1260,913347,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/8,Other,,
1261,913348,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/8,Other,,
1262,913349,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/8,Other,,
1263,913350,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/8,Other,,
1264,913351,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/8,Other,,
1265,913352,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/8,Other,,
1266,913353,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/9,Other,,
1267,913354,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/9,Other,,
1268,913355,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/9,Other,,
1269,913356,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/9,Other,,
1270,913357,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/9,Other,,
1271,913358,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/9,Other,,
1272,913359,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/9,Other,,
1273,913360,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/9,Other,,
1274,913361,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/9,Other,,
1275,913362,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/9,Other,,
1276,913363,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/9,Other,,
1277,913364,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/9,Other,,
1278,913365,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/9,Other,,
1279,913366,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/9,Other,,
1280,913367,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/9,Other,,
1281,913368,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/9,Other,,
1282,913369,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/9,Other,,
1283,913370,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/9,Other,,
1284,913371,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/9,Other,,
1285,913372,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/10,Other,,
1286,913373,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/10,Other,,
1287,913374,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/10,Other,,
1288,913375,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/10,Other,,
1289,913376,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/10,Other,,
1290,913377,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/10,Other,,
1291,913378,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/10,Other,,
1292,913379,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/10,Other,,
1293,913380,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/10,Other,,
1294,913381,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/10,Other,,
1295,913382,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/10,Other,,
1296,913383,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/10,Other,,
1297,913384,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/10,Other,,
1298,913385,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/10,Other,,
1299,913386,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/10,Other,,
1300,913764,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/10,Other,,
1301,914649,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/5,Other,,
1302,914650,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/5,Other,,
1303,914651,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/5,Other,,
1304,914652,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/5,Other,,
1305,914660,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/12,Other,,
1306,914661,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/12,Other,,
1307,914662,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/12,Other,,
1308,914663,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/13,Other,,
1309,914664,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/13,Other,,
1310,914665,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/13,Other,,
1311,914666,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/13,Other,,
1312,914667,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/13,Other,,
1313,914668,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/13,Other,,
1314,914669,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/13,Other,,
1315,914670,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/13,Other,,
1316,914671,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/13,Other,,
1317,914672,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/13,Other,,
1318,914673,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/13,Other,,
1319,914674,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/13,Other,,
1320,914675,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/13,Other,,
1321,914676,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/13,Other,,
1322,914677,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/13,Other,,
1323,914678,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/13,Other,,
1324,914679,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/13,Other,,
1325,914680,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/13,Other,,
1326,914681,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/13,Other,,
1327,914682,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/14,Other,,
1328,915123,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/14,Other,,
1329,915124,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/14,Other,,
1330,915125,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/14,Other,,
1331,915126,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/14,Other,,
1332,915127,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/14,Other,,
1333,915128,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/14,Other,,
1334,915129,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 718/14,Other,,
1335,915130,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 718/14,Other,,
1336,915131,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 718/14,Other,,
1337,915132,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 718/14,Other,,
1338,915133,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 718/14,Other,,
1339,915134,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 718/14,Other,,
1340,915135,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 718/14,Other,,
1341,915136,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 718/14,Other,,
1342,915137,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 718/14,Other,,
1343,915138,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 718/14,Other,,
1344,915139,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 718/14,Other,,
1345,915140,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 718/14,Other,,
1346,915141,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 718/15,Other,,
1347,915142,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 718/15,Other,,
1348,915143,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 718/15,Other,,
1349,915144,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 718/15,Other,,
1350,915145,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/15,Other,,
1351,915146,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 718/15,Other,,
1352,915147,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 718/15,Other,,
1353,915177,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/10,Other,,
1354,915178,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/10,Other,,
1355,915179,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/10,Other,,
1356,915180,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/11,Other,,
1357,915181,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/11,Other,,
1358,915182,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/11,Other,,
1359,915183,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/11,Other,,
1360,915184,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/11,Other,,
1361,915185,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/11,Other,,
1362,915186,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/11,Other,,
1363,915187,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/11,Other,,
1364,915188,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/11,Other,,
1365,915189,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/11,Other,,
1366,915190,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/11,Other,,
1367,915191,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/11,Other,,
1368,915192,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/11,Other,,
1369,915193,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/11,Other,,
1370,915194,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/11,Other,,
1371,915195,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/11,Other,,
1372,915196,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/11,Other,,
1373,915197,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/11,Other,,
1374,915198,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/11,Other,,
1375,915199,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/12,Other,,
1376,915200,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/12,Other,,
1377,915201,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/12,Other,,
1378,915202,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/12,Other,,
1379,915203,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/12,Other,,
1380,915204,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/12,Other,,
1381,915205,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 719/12,Other,,
1382,915206,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 719/12,Other,,
1383,915207,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 719/12,Other,,
1384,915208,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 719/12,Other,,
1385,915209,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 719/12,Other,,
1386,915210,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 719/12,Other,,
1387,915211,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 719/12,Other,,
1388,915212,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 719/12,Other,,
1389,915213,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 719/12,Other,,
1390,915600,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 719/12,Other,,
1391,915601,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 719/12,Other,,
1392,915602,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 719/12,Other,,
1393,915603,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 719/12,Other,,
1394,915604,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 719/13,Other,,
1395,915605,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 719/13,Other,,
1396,915606,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 719/13,Other,,
1397,915607,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 719/13,Other,,
1398,915608,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 719/13,Other,,
1399,915609,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 719/13,Other,,
1400,916006,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 718/5,Other,,
1401,928350,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020729,Other,,
1402,928351,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020729,Other,,
1403,928352,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020729,Other,,
1404,928353,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020729,Other,,
1405,928354,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020729,Other,,
1406,928355,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020729,Other,,
1407,928356,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020729",Other,,
1408,928357,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020729,Other,,
1409,928358,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020729,Other,,
1410,928359,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020729,Other,,
1411,928360,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020729,Other,,
1412,928361,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020729,Other,,
1413,928362,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020729,Other,,
1414,928363,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020729,Other,,
1415,928364,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020729,Other,,
1416,928365,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020729,Other,,
1417,928366,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020729,Other,,
1418,928367,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020729,Other,,
1419,928368,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020729,Other,,
1420,940985,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020729,Other,,
1421,940986,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020729,Other,,
1422,940987,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020729,Other,,
1423,940988,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020729,Other,,
1424,940989,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020729,Other,,
1425,940990,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020729,Other,,
1426,940991,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020729,Other,,
1427,940992,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020729,Other,,
1428,940993,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020729,Other,,
1429,940994,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020729,Other,,
1430,940995,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020729,Other,,
1431,940996,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020729,Other,,
1432,940997,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020729",Other,,
1433,940998,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020729,Other,,
1434,943018,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020729,Other,,
1435,943019,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020729,Other,,
1436,943020,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020729,Other,,
1437,943021,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020729,Other,,
1438,943022,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020729,Other,,
1439,963112,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020729,Other,,
1440,963113,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020729,Other,,
1441,963114,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020729,Other,,
1442,963115,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020729,Other,,
1443,963116,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020729,Other,,
1444,963117,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020729,Other,,
1445,963118,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020729,Other,,
1446,963119,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020729,Other,,
1447,963120,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020729,Other,,
1448,963121,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020729,Other,,
1449,963122,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020729,Other,,
1450,963123,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020729,Other,,
1451,963124,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020729,Other,,
1452,963125,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020729,Other,,
1453,963126,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020729,Other,,
1454,963127,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020729,Other,,
1455,963128,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020729,Other,,
1456,963129,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020729,Other,,
1457,963130,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020729,Other,,
1458,974713,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020729,Other,,
1459,974714,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020729,Other,,
1460,974715,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020729,Other,,
1461,974716,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020729,Other,,
1462,974717,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020729,Other,,
1463,974718,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020729,Other,,
1464,974719,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020729,Other,,
1465,974720,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020729,Other,,
1466,974721,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020729,Other,,
1467,974722,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020729,Other,,
1468,974723,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020729,Other,,
1469,974724,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020729,Other,,
1470,974725,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020729,Other,,
1471,974726,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020729,Other,,
1472,974727,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020729,Other,,
1473,974728,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020729,Other,,
1474,974729,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020729,Other,,
1475,974730,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020729,Other,,
1476,974731,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020729,Other,,
1477,985861,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S020729",Other,,
1478,985862,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S020729",Other,,
1479,985863,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S020729",Other,,
1480,986446,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S020729",Other,,
1481,986447,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020729",Other,,
1482,986448,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020729",Other,,
1483,986449,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S020729",Other,,
1484,986450,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020729",Other,,
1485,986451,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020729,Other,,
1486,986452,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020729",Other,,
1487,986453,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020729",Other,,
1488,986454,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020729",Other,,
1489,986455,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
1490,986456,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S020729",Other,,
1491,986457,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S020729",Other,,
1492,986458,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
1493,986459,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020729",Other,,
1494,986460,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020729",Other,,
1495,986461,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020729",Other,,
1496,986462,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020729,Other,,
1497,986463,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020729",Other,,
1498,986464,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020729",Other,,
1499,986465,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020729",Other,,
1500,986466,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020729",Other,,
1501,986467,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020729",Other,,
1502,986468,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020729",Other,,
1503,986469,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
1504,986470,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S020729",Other,,
1505,989679,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
1506,989680,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020729",Other,,
1507,989681,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S020729,Other,,
1508,989682,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020729",Other,,
1509,989683,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020729",Other,,
1510,989684,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020729",Other,,
1511,989685,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020729",Other,,
1512,991550,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020729",Other,,
1513,991551,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020729",Other,,
1514,991552,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020729",Other,,
1515,991553,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020729",Other,,
1516,991554,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020729",Other,,
1517,991555,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S020729",Other,,
1518,991556,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S020729",Other,,
1519,991557,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S020729",Other,,
1520,991558,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S020729",Other,,
1521,991559,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020729,Other,,
1522,991560,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020729",Other,,
1523,991561,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020729,Other,,
1524,991562,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020729",Other,,
1525,992148,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020729",Other,,
1526,992149,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020729",Other,,
1527,992150,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020729",Other,,
1528,992151,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020729",Other,,
1529,992152,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020729",Other,,
1530,992153,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020729",Other,,
1531,992154,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020729",Other,,
1532,992155,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020729",Other,,
1533,992156,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
1534,992157,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020729",Other,,
1535,992158,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020729",Other,,
1536,992159,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S020729",Other,,
1537,992160,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S020729,Other,,
1538,992161,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
1539,992162,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020729",Other,,
1540,992163,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
1541,992164,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020729",Other,,
1542,992165,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020729",Other,,
1543,992166,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020729",Other,,
1544,992167,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020729",Other,,
1545,992168,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020729",Other,,
1546,992169,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020729",Other,,
1547,992170,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020729",Other,,
1548,992171,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020729",Other,,
1549,992172,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020729",Other,,
1550,992173,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020729",Other,,
1551,992174,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020729",Other,,
1552,994038,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020729",Other,,
1553,994039,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S020729",Other,,
1554,994040,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S020729",Other,,
1555,994041,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S020729",Other,,
1556,994042,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020729",Other,,
1557,994043,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020729",Other,,
1558,994044,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020729,Other,,
1559,994623,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020729,Other,,
1560,994624,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020729",Other,,
1561,994625,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020729",Other,,
1562,994626,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020729",Other,,
1563,994627,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020729",Other,,
1564,994628,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
1565,994629,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020729",Other,,
1566,994630,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S020729",Other,,
1567,994631,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S020729",Other,,
1568,994632,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S020729",Other,,
1569,994633,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S020729",Other,,
1570,994634,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020729",Other,,
1571,994635,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020729",Other,,
1572,994636,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020729",Other,,
1573,994637,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020729",Other,,
1574,994638,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020729,Other,,
1575,994639,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S020729",Other,,
1576,994640,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
1577,994641,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020729",Other,,
1578,994642,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020729",Other,,
1579,994643,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020729",Other,,
1580,994644,1,3,,103164951,4946,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020729,Other,,
1581,994645,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020729",Other,,
1582,994646,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020729",Other,,
1583,994647,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020729",Other,,
1584,994648,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020729",Other,,
1585,994649,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S020729",Other,,
1586,994650,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S020729",Other,,
1587,994651,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020729",Other,,
1588,994652,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020729",Other,,
1589,994653,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020729",Other,,
1590,994654,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020729",Other,,
1591,994655,1,3,,103164951,4946,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020729",Other,,
1592,1047016,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/5,Other,,
1593,1047017,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/5,Other,,
1594,1047018,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/5,Other,,
1595,1047019,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/5,Other,,
1596,1047020,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/5,Other,,
1597,1047021,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/6,Other,,
1598,1047022,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/6,Other,,
1599,1047023,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/6,Other,,
1600,1047024,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/6,Other,,
1601,1047025,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/6,Other,,
1602,1047026,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/7,Other,,
1603,1047027,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/7,Other,,
1604,1047028,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/7,Other,,
1605,1047029,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/7,Other,,
1606,1047030,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/7,Other,,
1607,1047031,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/8,Other,,
1608,1047032,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/8,Other,,
1609,1047033,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/8,Other,,
1610,1047034,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/8,Other,,
1611,1047035,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/8,Other,,
1612,1047036,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/9,Other,,
1613,1047037,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/9,Other,,
1614,1047038,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/9,Other,,
1615,1047039,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/9,Other,,
1616,1047040,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/9,Other,,
1617,1047041,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/10,Other,,
1618,1047042,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/10,Other,,
1619,1047131,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/10,Other,,
1620,1047132,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/10,Other,,
1621,1047133,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/10,Other,,
1622,1047134,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/11,Other,,
1623,1047135,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/11,Other,,
1624,1047136,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/11,Other,,
1625,1047137,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/11,Other,,
1626,1047180,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/9,Other,,
1627,1047181,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/9,Other,,
1628,1047182,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/9,Other,,
1629,1047183,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/9,Other,,
1630,1047184,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/10,Other,,
1631,1047185,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/10,Other,,
1632,1047186,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/10,Other,,
1633,1047187,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/10,Other,,
1634,1047188,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/10,Other,,
1635,1047189,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/11,Other,,
1636,1047190,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/11,Other,,
1637,1047191,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/11,Other,,
1638,1047192,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/11,Other,,
1639,1047193,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/11,Other,,
1640,1047194,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/12,Other,,
1641,1047195,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/12,Other,,
1642,1047196,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/12,Other,,
1643,1047197,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/12,Other,,
1644,1047198,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/12,Other,,
1645,1047199,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/13,Other,,
1646,1047200,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/13,Other,,
1647,1047201,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/13,Other,,
1648,1047202,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/13,Other,,
1649,1047203,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/13,Other,,
1650,1047204,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/14,Other,,
1651,1047205,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/14,Other,,
1652,1047206,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/14,Other,,
1653,1047207,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/14,Other,,
1654,1047208,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/14,Other,,
1655,1047209,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/15,Other,,
1656,1047210,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/15,Other,,
1657,1047211,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/15,Other,,
1658,1047212,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/15,Other,,
1659,1047213,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/15,Other,,
1660,1047214,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/16,Other,,
1661,1047215,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/16,Other,,
1662,1047216,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/16,Other,,
1663,1047217,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/16,Other,,
1664,1047351,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/16,Other,,
1665,1047451,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/11,Other,,
1666,1047452,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/12,Other,,
1667,1047453,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/12,Other,,
1668,1047454,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/12,Other,,
1669,1047455,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/12,Other,,
1670,1047456,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/12,Other,,
1671,1047457,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/13,Other,,
1672,1047458,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/13,Other,,
1673,1047459,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/13,Other,,
1674,1047460,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/13,Other,,
1675,1047461,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/13,Other,,
1676,1047462,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/14,Other,,
1677,1047463,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/14,Other,,
1678,1047464,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/14,Other,,
1679,1047465,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/14,Other,,
1680,1047466,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/14,Other,,
1681,1047467,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/15,Other,,
1682,1047468,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/15,Other,,
1683,1047469,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/15,Other,,
1684,1047470,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/15,Other,,
1685,1047471,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/15,Other,,
1686,1047472,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 718/16,Other,,
1687,1047473,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 718/16,Other,,
1688,1047474,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 718/16,Other,,
1689,1047475,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 718/16,Other,,
1690,1047476,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 718/16,Other,,
1691,1047477,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/5,Other,,
1692,1047478,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/5,Other,,
1693,1047479,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/5,Other,,
1694,1047480,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/5,Other,,
1695,1047481,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/5,Other,,
1696,1047482,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/6,Other,,
1697,1047483,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/6,Other,,
1698,1047484,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/6,Other,,
1699,1047619,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/6,Other,,
1700,1047620,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/6,Other,,
1701,1047621,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/7,Other,,
1702,1047622,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/7,Other,,
1703,1047623,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/7,Other,,
1704,1047624,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/7,Other,,
1705,1047625,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/7,Other,,
1706,1047626,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/8,Other,,
1707,1047627,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 719/8,Other,,
1708,1047628,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 719/8,Other,,
1709,1047629,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 719/8,Other,,
1710,1047630,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 719/8,Other,,
1711,1047631,1,2,,103164951,4946,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 719/9,Other,,
1712,1053287,1,2,,103164951,4946,Unspecified,,,,,Fraction unbound in rat plasma at 5 uM after 4 hrs by equilibrium dialysis method,Other,24047231.0,
1713,1061255,4,2,,103164951,4946,Active,296439450.0,154.0,0.0036899999999999997,Ki,"Displacement of [3H]-(R,R')-methoxyfenoterol from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis",Confirmatory,24326276.0,
1714,1061256,2,3,,103164951,4946,Active,296439450.0,154.0,0.00045999999999999996,Ki,Displacement of [3H]-CGP-12177 from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis,Confirmatory,24326276.0,
1715,1061889,1,2,,103164951,4946,Unspecified,,,,IC50,Displacement of [3H]BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes after 60 mins by scintillation counting,Confirmatory,24332655.0,
1716,1067798,1,1,,103164951,4946,Unspecified,,,,,Apparent permeability across MDCK2 cells expressing human MDR1,Other,24354316.0,
1717,1067808,1,1,,103164951,4946,Unspecified,,,,,Apparent permeability across MDCK2 cells expressing human MDR1 in presence of GF120918,Other,24354316.0,
1718,1074028,1,2,,103164951,4946,Unspecified,,,,,Efflux ratio of permeability in pig LLC-PK1 cells transfected with human MDR1 at 1 uM by LC-MS/MS analysis,Other,24397738.0,
1719,1074030,1,2,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side in pig LLC-PK1 cells by LC-MS/MS analysis,Other,24397738.0,
1720,1075746,1,2,,103164951,4946,Unspecified,,,,,Half life in human liver microsomes at 1 uM by LC-MS analysis,Other,24502232.0,
1721,1079931,1,1,,103164951,4946,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1722,1079932,1,1,,103164951,4946,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1723,1079933,1,1,,103164951,4946,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1724,1079934,1,1,,103164951,4946,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1725,1079935,1,1,,103164951,4946,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1726,1079936,1,1,,103164951,4946,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1727,1079937,1,1,,103164951,4946,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1728,1079938,1,1,,103164951,4946,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1729,1079939,1,1,,103164951,4946,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1730,1079940,1,1,,103164951,4946,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1731,1079941,1,1,,103164951,4946,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1732,1079942,1,1,,103164951,4946,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1733,1079943,1,1,,103164951,4946,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1734,1079944,1,1,,103164951,4946,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1735,1079945,1,1,,103164951,4946,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1736,1079946,1,1,,103164951,4946,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1737,1079947,1,1,,103164951,4946,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1738,1079948,1,1,,103164951,4946,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1739,1079949,1,1,,103164951,4946,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1740,1091955,1,2,,103164951,4946,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
1741,1091956,1,1,,103164951,4946,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
1742,1091957,1,1,,103164951,4946,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
1743,1091958,2,1,,103164951,4946,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
1744,1094304,2,3,,103164951,4946,Inconclusive,112808.0,29595.0,,Ki,Displacement of [3H]Ketanserin from 5HT2A receptor in Rattus norvegicus (rat) cerebral cortex by filter binding assay,Confirmatory,,
1745,1094305,2,3,,103164951,4946,Inconclusive,112812.0,24473.0,,Ki,Displacement of [3H]8-OH-DPAT from 5HT1A receptor in Rattus norvegicus (rat) cerebral cortex after 15 min by filter binding assay,Confirmatory,,
1746,1094306,2,3,,103164951,4946,Active,114754.0,24925.0,0.003,Ki,Displacement of [3H]CGP12177 from beta1 adrenoreceptor in Rattus norvegicus (rat) cerebral cortex by liquid scintillation counting,Confirmatory,,
1747,1095826,1,2,,103164951,4946,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as Rmax at 10 mg/kg, ip measured after 60 min by ECG analysis (Rvb = 0.07 +/- 0.004 mv)",Other,,
1748,1095830,1,2,,103164951,4946,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as Rmax at 10 mg/kg, ip measured after 45 min by ECG analysis (Rvb = 0.08 +/- 0.008 mv)",Other,,
1749,1095834,1,2,,103164951,4946,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as Rmax at 10 mg/kg, ip measured after 30 min by ECG analysis (Rvb = 0.08 +/- 0.008 mv)",Other,,
1750,1095838,1,3,,103164951,4946,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as heart rate at 10 mg/kg, ip measured after 60 min by ECG analysis (Rvb = 307.62 +/- 0.053 bpm)",Other,,
1751,1095842,1,3,,103164951,4946,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as heart rate at 10 mg/kg, ip measured after 45 min by ECG analysis (Rvb = 307.62 +/- 0.023 bpm)",Other,,
1752,1095846,1,3,,103164951,4946,Unspecified,,,,,"Toxicity in Rattus norvegicus Wistar (rat) assessed as heart rate at 10 mg/kg, ip measured after 30 min by ECG analysis (Rvb = 307.62 +/- 0.035 bpm)",Other,,
1753,1097336,1,3,,103164951,4946,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
1754,1106475,1,4,,103164951,4946,Unspecified,114754.0,24925.0,,,Inhibition of beta-adrenergic receptor in Rattus norvegicus albino (rat) aortic ring assessed as norepinephrine-induced contraction at 1 uM measured for 1 to 2 min (Rvb = 51.18%),Other,,
1755,1106476,1,4,,103164951,4946,Unspecified,114754.0,24925.0,,,Inhibition of beta-adrenergic receptor in Rattus norvegicus albino (rat) norepinephrine-contracted aortic ring assessed as change in isoprenaline-induced relaxation at 1 uM measured for 1 to 2 min (Rvb = 19.75%),Other,,
1756,1123427,2,2,,103164951,4946,Active,,,0.00955,Kd,Competitive antagonist activity at beta-1 adrenergic receptor in guinea pig assessed as inhibition of isoproterenol-induced atrial beat rate,Confirmatory,34040.0,
1757,1123428,2,2,,103164951,4946,Active,,,0.014130000000000002,Kd,Competitive antagonist activity at beta-1 adrenergic receptor in guinea pig assessed as inhibition of isoproterenol-induced atrial contractile force,Confirmatory,34040.0,
1758,1123429,2,2,,103164951,4946,Active,81914759.0,100722663.0,0.014790000000000001,Kd,Competitive antagonist activity at beta-2 adrenergic receptor in guinea pig assessed as inhibition of isoproterenol-induced tracheal relaxation,Confirmatory,34040.0,
1759,1123430,1,3,,103164951,4946,Unspecified,81914759.0,100722663.0,,,Competitive antagonist activity at beta-2 adrenergic receptor in guinea pig assessed as inhibition of isoproterenol-induced tracheal relaxation relative to propranolol,Other,34040.0,
1760,1123536,1,3,,103164951,4946,Active,114754.0,24925.0,,,Displacement of [3H]DHA from beta1 adrenergic receptor in rat ventricular muscle by competitive binding assay,Other,37339.0,
1761,1123537,1,3,,103164951,4946,Active,114768.0,24176.0,,,Displacement of [3H]DHA from beta2 adrenergic receptor in rat lung muscle by competitive binding assay,Other,37339.0,
1762,1123538,1,1,,103164951,4946,Unspecified,,,,,Cardio selectivity ratio of Kapp for beta2 adrenergic receptor in rat lung muscle to Kapp for beta1 adrenergic receptor in rat ventricular muscle,Other,37339.0,
1763,1124840,1,2,,103164951,4946,Unspecified,,,,,Apparent permeability coefficient in Sprague-Dawley rat jejunum,Other,24630695.0,
1764,1125242,1,1,,103164951,4946,Unspecified,,,,,"Toxicity in DOCA-induced normotensive Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip measured immediately at 0 min (Rvb = 94.21 +/- 2.065 mmHg)",Other,24637077.0,
1765,1125243,1,1,,103164951,4946,Unspecified,,,,,"Toxicity in DOCA-induced normotensive Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip after 15 mins (Rvb = 93.81 +/- 1.543 mmHg)",Other,24637077.0,
1766,1125244,1,1,,103164951,4946,Unspecified,,,,,"Toxicity in DOCA-induced normotensive Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip after 30 mins (Rvb = 94.68 +/- 1.213 mmHg)",Other,24637077.0,
1767,1125245,1,1,,103164951,4946,Unspecified,,,,,"Toxicity in DOCA-induced normotensive Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip after 45 mins (Rvb = 94.83 +/- 0.943 mmHg)",Other,24637077.0,
1768,1125246,1,1,,103164951,4946,Unspecified,,,,,"Toxicity in DOCA-induced normotensive Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip after 60 mins (Rvb = 95.07 +/- 1.973 mmHg)",Other,24637077.0,
1769,1125252,1,1,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip measured immediately at 0 min (Rvb = 194.08 +/- 1.962 mmHg)",Other,24637077.0,
1770,1125253,1,1,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip measured immediately at 15 mins (Rvb = 195.68 +/- 1.623 mmHg)",Other,24637077.0,
1771,1125254,1,1,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip measured immediately at 30 mins (Rvb = 194.72 +/- 1.002 mmHg)",Other,24637077.0,
1772,1125255,1,1,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip measured immediately at 45 mins (Rvb = 193.96 +/- 0.865 mmHg)",Other,24637077.0,
1773,1125256,1,1,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in Wistar rat assessed as mean arterial pressure at 10 mg/kg, ip measured immediately at 60 mins (Rvb = 195.11 +/- 0.531 mmHg)",Other,24637077.0,
1774,1129361,1,1,,103164951,4946,Unspecified,,,,,Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis,Other,24601604.0,
1775,1129458,1,2,,103164951,4946,Unspecified,,,,,Protein binding in plasma (unknown origin) at 5 uM after 4 hrs,Other,24602787.0,
1776,1135145,1,2,,103164951,4946,Active,,,0.0063100000000000005,Kd,Antagonist activity at guinea pig atrial beta adrenergic receptor assessed as isometric contractions by force displacement transducer,Confirmatory,15112.0,
1777,1135149,1,2,,103164951,4946,Unspecified,,,,,"Hypotensive activity at guinea pig assessed as decrease in blood pressure at 50 mg/kg, po after 1 hr (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)",Other,15112.0,
1778,1135150,1,2,,103164951,4946,Unspecified,,,,,"Hypotensive activity at guinea pig assessed as decrease in blood pressure at 50 mg/kg, po after 3 hrs (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)",Other,15112.0,
1779,1135151,1,2,,103164951,4946,Unspecified,,,,,"Hypotensive activity at guinea pig assessed as decrease in blood pressure at 50 mg/kg, po after 5 hrs (Rvb = 112 +/- 2.6 to 122 +/- 2.7 mmHg)",Other,15112.0,
1780,1135310,1,1,,103164951,4946,Unspecified,,,,,In vivo inhibition of beta-1 adrenergic receptor in cat assessed as inhibition of isoproterenol-induced tachycardia administered as 30 mins of infusion measured at 30 mins by cardiotachometer,Other,16137.0,
1781,1135311,1,1,,103164951,4946,Unspecified,,,,,In vivo inhibition of beta-2 adrenergic receptor in cat assessed as inhibition of isoproterenol-induced vasodepressor response at ED50 administered as 30 mins of infusion measured at 30 mins relative to control,Other,16137.0,
1782,1135364,1,1,,103164951,4946,Unspecified,,,,,"In vivo inhibition of beta-adrenoceptor in Wistar rat assessed as inhibition of isoproterenol-induced tachycardia at 4 mg/kg, iv relative to control",Other,17752.0,
1783,1135365,1,2,,103164951,4946,Unspecified,,,,,"In vivo inhibition of beta-adrenoceptor in Wistar rat assessed as decrease in heart rate at 4 mg/kg, iv relative to control",Other,17752.0,
1784,1135366,1,1,,103164951,4946,Unspecified,,,,,"In vivo inhibition of beta-adrenoceptor in cat assessed as inhibition of isoproterenol-induced tachycardia at 0.1 mg/kg, iv relative to control",Other,17752.0,
1785,1135367,1,1,,103164951,4946,Unspecified,,,,,"In vivo inhibition of beta-adrenoceptor in cat assessed as inhibition of isoproterenol-induced tachycardia at 1 mg/kg, iv relative to control",Other,17752.0,
1786,1135368,1,1,,103164951,4946,Unspecified,,,,,"In vivo inhibition of beta-adrenoceptor in cat assessed as inhibition of isoproterenol-induced hypotension at 0.1 mg/kg, iv relative to control",Other,17752.0,
1787,1135369,1,1,,103164951,4946,Unspecified,,,,,"In vivo inhibition of beta-adrenoceptor in cat assessed as inhibition of isoproterenol-induced hypotension at 1 mg/kg, iv relative to control",Other,17752.0,
1788,1135371,1,1,,103164951,4946,Unspecified,,,,,"In vivo inhibition of beta-adrenoceptor in histamine-treated guinea pig assessed as inhibition of isoproterenol-induced bronchodilator effect at 0.1 mg/kg, iv administered 3 mins prior to histamine/isoproterenol challenge relative to control",Other,17752.0,
1789,1135372,1,1,,103164951,4946,Active,,,,,"In vivo inhibition of beta-adrenoceptor in histamine-treated guinea pig assessed as inhibition of isoproterenol-induced bronchodilator effect at 0.01 mg/kg, iv administered 3 mins prior to histamine/isoproterenol challenge relative to control",Other,17752.0,
1790,1135373,1,1,,103164951,4946,Unspecified,,,,,"Local anesthetic activity in ICR Swiss mouse assessed as inhibition of pain reflex response at 0.5%, id relative to control",Other,17752.0,
1791,1135374,1,1,,103164951,4946,Active,,,,,"Local anesthetic activity in ICR Swiss mouse assessed as inhibition of pain reflex response at 1%, id relative to control",Other,17752.0,
1792,1135375,1,1,,103164951,4946,Unspecified,,,,,Acute toxicity in iv dosed mouse,Other,17752.0,
1793,1135962,1,2,,103164951,4946,Unspecified,,,,,"Reversal of epinephrine-induced increase in mean arterial blood pressure in cat at 2.5 mg/kg, iv",Other,22756.0,
1794,1135963,1,2,,103164951,4946,Unspecified,,,,,"Reversal of isoproterenol-induced increase in mean arterial blood pressure in cat assessed as depressor phase at 2.5 mg/kg, iv",Other,22756.0,
1795,1135964,2,2,,103164951,4946,Active,81914759.0,100722663.0,0.24088,Kd,Inhibition of beta2-adrenergic receptor in guinea pig tracheal chain assessed as reversal of isoproterenol-induced effect after 15 mins,Confirmatory,22756.0,
1796,1135965,2,1,,103164951,4946,Active,,,0.2534,Kd,Inhibition of beta1-adrenergic receptor in guinea pig auricle assessed as reversal of isoproterenol-induced effect,Confirmatory,22756.0,
1797,1135972,1,1,,103164951,4946,Inactive,,,,,Anesthetic effect in guinea pig at 0.1 % by intradermal wheal method,Other,22756.0,
1798,1135973,1,2,,103164951,4946,Inactive,,,,,Antiarrhythmic activity against guinea pig auricle,Other,22756.0,
1799,1136324,2,2,,103164951,4946,Active,,,0.002,Kd,Antagonist activity at beta1 adrenoceptor in guinea pig atrium assessed as inhibition of isoproterenol-induced response after 20 mins,Confirmatory,31474.0,
1800,1136325,1,2,,103164951,4946,Unspecified,,,,,Intrinsic activity at beta1 adrenoceptor in guinea pig atrium after 20 mins relative to control,Other,31474.0,
1801,1136326,2,2,,103164951,4946,Active,81914759.0,100722663.0,0.0013800000000000002,Kd,Antagonist activity at beta2 adrenoceptor in guinea pig trachea assessed as inhibition of isoproterenol-induced response after 20 mins,Confirmatory,31474.0,
1802,1136327,1,3,,103164951,4946,Unspecified,81914759.0,100722663.0,,,Intrinsic activity at beta2 adrenoceptor in guinea pig trachea after 20 mins,Other,31474.0,
1803,1136404,1,2,,103164951,4946,Unspecified,,,,,Inhibition of beta-adrenergic receptor in isoproterenol-stimulated guinea pig atrial muscle,Other,31485.0,
1804,1136407,1,2,,103164951,4946,Unspecified,,,,,Myocardial depressant activity in guinea pig atrial muscle assessed as maximal non-depressant dose by measuring contractility,Other,31485.0,
1805,1137302,1,2,,103164951,4946,Unspecified,,,,,Antiarrhythmic activity in New Zealand White rabbit isolated atria assessed as reduction of maximum driving frequency after 15 mins,Other,423187.0,
1806,1137304,1,1,,103164951,4946,Unspecified,,,,,Negative inotropic activity in New Zealand White rabbit isolated atria assessed as reduction of tissue contractility after 15 mins,Other,423187.0,
1807,1137306,1,1,,103164951,4946,Unspecified,,,,,"Selectivity index, ratio of pED40 for tissue contractility to pED40 for maximum driving response in New Zealand White rabbit isolated atria",Other,423187.0,
1808,1137307,2,1,,103164951,4946,Unspecified,,,,,"Octanol-phosphate buffer partition coefficient, log P of the compound",Other,423187.0,
1809,1137372,1,1,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 1.25 mg/kg, po",Other,42797.0,
1810,1137373,1,1,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 5 mg/kg, po",Other,42797.0,
1811,1137374,1,1,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as maximal fall in mean arterial pressure at 20 mg/kg, po",Other,42797.0,
1812,1137383,1,1,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as duration of action at 1.25 mg/kg, po",Other,42797.0,
1813,1137384,1,1,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as duration of action at 5 mg/kg, po",Other,42797.0,
1814,1137385,1,1,,103164951,4946,Unspecified,,,,,"Antihypertensive activity in spontaneously hypertensive Wistar-Okamoto rat assessed as duration of action at 20 mg/kg, po",Other,42797.0,
1815,1137402,1,1,,103164951,4946,Unspecified,,,,,In vivo beta-adrenergic receptor blockade in iv dosed anesthetized dog assessed as inhibition of isoproterenol-induced hypotension,Other,42797.0,
1816,1137403,1,1,,103164951,4946,Unspecified,,,,,In vivo beta-adrenergic receptor blockade in iv dosed anesthetized dog assessed as inhibition of isoproterenol-induced tachycardia,Other,42797.0,
1817,1145697,1,2,,103164951,4946,Active,,,,,Negative chronotropic activity in guinea pig right atrium assessed as atrial rate at MEC after 30 mins,Other,15113.0,
1818,1145698,1,2,,103164951,4946,Active,,,,,Negative inotropic activity in guinea pig right atrium assessed as contractile force at MEC after 30 mins,Other,15113.0,
1819,1146353,1,2,,103164951,4946,Unspecified,,,,,"Inhibition of isoproterenol-induced decrease in diastolic blood pressure in bilaterally vagotomized open chest mongrel dog model at 1.45 mg/kg, iv administered 10 to 20 mins prior to and following isoproterenol challenge",Other,22752.0,
1820,1146354,1,2,,103164951,4946,Unspecified,,,,,"Inhibition of isoproterenol-induced decrease in diastolic blood pressure in bilaterally vagotomized open chest mongrel dog model at 4.61 mg/kg, iv administered 10 to 20 mins prior to and following isoproterenol challenge",Other,22752.0,
1821,1146365,1,2,,103164951,4946,Unspecified,,,,,Inhibition of isoproterenol-induced increase in heart rate in iv dosed bilaterally vagotomized open chest mongrel dog model administered 10 to 20 mins prior to and following isoproterenol challenge,Other,22752.0,
1822,1146366,1,2,,103164951,4946,Unspecified,,,,,Inhibition of isoproterenol-induced decrease in diastolic blood pressure in iv dosed bilaterally vagotomized open chest mongrel dog model administered 10 to 20 mins prior to and following isoproterenol challenge,Other,22752.0,
1823,1146367,1,2,,103164951,4946,Unspecified,,,,,"Inhibition of isoproterenol-induced increase in heart rate in bilaterally vagotomized open chest mongrel dog model at 0.03 mg/kg, iv administered 10 to 20 mins prior to and following isoproterenol challenge",Other,22752.0,
1824,1146368,1,2,,103164951,4946,Unspecified,,,,,"Inhibition of isoproterenol-induced increase in heart rate in bilaterally vagotomized open chest mongrel dog model at 0.13 mg/kg, iv administered 10 to 20 mins prior to and following isoproterenol challenge",Other,22752.0,
1825,1146369,1,2,,103164951,4946,Unspecified,,,,,"Inhibition of isoproterenol-induced increase in heart rate in bilaterally vagotomized open chest mongrel dog model at 0.45 mg/kg, iv administered 10 to 20 mins prior to and following isoproterenol challenge",Other,22752.0,
1826,1146370,1,2,,103164951,4946,Unspecified,,,,,"Inhibition of isoproterenol-induced increase in heart rate in bilaterally vagotomized open chest mongrel dog model at 1.45 mg/kg, iv administered 10 to 20 mins prior to and following isoproterenol challenge",Other,22752.0,
1827,1146371,1,2,,103164951,4946,Unspecified,,,,,"Inhibition of isoproterenol-induced increase in heart rate in bilaterally vagotomized open chest mongrel dog model at 4.61 mg/kg, iv administered 10 to 20 mins prior to and following isoproterenol challenge",Other,22752.0,
1828,1146372,1,2,,103164951,4946,Unspecified,,,,,"Inhibition of isoproterenol-induced decrease in diastolic blood pressure in bilaterally vagotomized open chest mongrel dog model at 0.03 mg/kg, iv administered 10 to 20 mins prior to and following isoproterenol challenge",Other,22752.0,
1829,1146373,1,2,,103164951,4946,Unspecified,,,,,"Inhibition of isoproterenol-induced decrease in diastolic blood pressure in bilaterally vagotomized open chest mongrel dog model at 0.13 mg/kg, iv administered 10 to 20 mins prior to and following isoproterenol challenge",Other,22752.0,
1830,1146374,1,2,,103164951,4946,Unspecified,,,,,"Inhibition of isoproterenol-induced decrease in diastolic blood pressure in bilaterally vagotomized open chest mongrel dog model at 0.45 mg/kg, iv administered 10 to 20 mins prior to and following isoproterenol challenge",Other,22752.0,
1831,1159524,1,1,,124881056,4946,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1832,1159580,2,1,,268735073,4946,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1833,1159580,2,1,,273002923,4946,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1834,1159580,2,1,,273002976,4946,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1835,1159607,2,1,,312309895,4946,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1836,1161000,1,1,,103164951,4946,Unspecified,,,,,Apparent permeability of the compound at pH 7.4 buffer by PAMPA,Other,25149511.0,
1837,1171959,1,2,,103164951,4946,Unspecified,,,,,Half life in CD-1 mouse liver microsomes at 0.75 uM incubated for 5 mins prior to NADPH addition measured after 30 mins by LC/MS/MS analysis,Other,25432025.0,
1838,1171960,1,2,,103164951,4946,Unspecified,,,,,Intrinsic clearance in CD-1 mouse liver microsomes at 0.75 uM incubated for 5 mins prior to NADPH addition measured after 30 mins by LC/MS/MS analysis,Other,25432025.0,
1839,1171961,1,2,,103164951,4946,Unspecified,,,,,Apparent clearance in CD-1 mouse liver microsomes at 0.75 uM incubated for 5 mins prior to NADPH addition measured after 30 mins by LC/MS/MS analysis,Other,25432025.0,
1840,1171962,1,2,,103164951,4946,Unspecified,,,,,Hepatic clearance in CD-1 mouse liver microsomes at 0.75 uM incubated for 5 mins prior to NADPH addition measured after 30 mins by LC/MS/MS analysis,Other,25432025.0,
1841,1171974,1,1,,103164951,4946,Unspecified,,,,,Hepatic extraction ratio in CD-1 mouse liver microsomes at 0.75 uM incubated for 5 mins prior to NADPH addition measured after 30 mins by LC/MS/MS analysis relative to control,Other,25432025.0,
1842,1195137,1,1,,103164951,4946,Unspecified,,,,,Permeability of the compound in DMSO/Prisma HT buffer at 1:200 ratio after 2 hrs by PAMPA-BBB assay,Other,25868744.0,
1843,1203133,1,1,,103164951,4946,Unspecified,,,,,Apparent permeability of the compound at RT after 24 hrs by PAMPA,Other,25730130.0,
1844,1203209,1,1,,103164951,4946,Unspecified,,,,,Apparent permeability across apical to basolateral side in human Caco2 cells in presence of 0.1% bovine serum albumin,Other,25738882.0,
1845,1203210,1,1,,103164951,4946,Unspecified,,,,,Apparent permeability across basolateral to apical side in human Caco2 cells in presence of 0.1% bovine serum albumin,Other,25738882.0,
1846,1203236,1,1,,103164951,4946,Unspecified,,,,,Ratio of apparent permeability across apical to basolateral over basolateral to apical side in human Caco2 cells in presence of 0.1% bovine serum albumin,Other,25738882.0,
1847,1207022,1,1,,103164951,4946,Unspecified,,,,,Permeability of the compound at pH 5 by PAMPA,Other,25958244.0,
1848,1207023,1,1,,103164951,4946,Unspecified,,,,,Permeability of the compound at pH 6.2 by PAMPA,Other,25958244.0,
1849,1207024,1,1,,103164951,4946,Unspecified,,,,,Permeability of the compound at pH 7.4 by PAMPA,Other,25958244.0,
1850,1207168,1,2,,103164951,4946,Active,215273881.0,6331.0,2.1,IC50,Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA,Confirmatory,21300721.0,
1851,1207197,1,2,,103164951,4946,Active,5921694.0,100135490.0,18.0,IC50,Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes,Confirmatory,21300721.0,
1852,1207227,1,1,,103164951,4946,Active,,,2.8280000000000003,IC50,Inhibition of hERG K channel,Confirmatory,21300721.0,
1853,1207258,1,2,,103164951,4946,Active,,,,,Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Other,21300721.0,
1854,1207690,1,2,,103164951,4946,Active,5921694.0,100135490.0,18.0,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Confirmatory,22761000.0,
1855,1207691,1,2,,103164951,4946,Active,308153651.0,775.0,21.0,IC50,Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit,Confirmatory,22761000.0,
1856,1209455,1,2,,103164951,4946,Unspecified,262527527.0,8647.0,1000.0,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
1857,1209456,1,2,,103164951,4946,Unspecified,12585136.0,83569.0,1000.0,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
1858,1209457,1,1,,103164951,4946,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
1859,1209581,1,2,,103164951,4946,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
1860,1209582,1,1,,103164951,4946,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
1861,1209583,1,1,,103164951,4946,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
1862,1209584,1,1,,103164951,4946,Inactive,,,,,Drug uptake in Sprague-Dawley rat brain slices in presence of 50 pM to 50 nM of monensin,Other,21149540.0,
1863,1209593,1,1,,103164951,4946,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
1864,1210069,1,2,,103164951,4946,Unspecified,21264413.0,1573.0,50.0,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
1865,1211293,1,2,,103164951,4946,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
1866,1211294,1,1,,103164951,4946,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
1867,1211295,1,1,,103164951,4946,Unspecified,,,,,Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO2,Other,21098647.0,
1868,1211296,1,2,,103164951,4946,Unspecified,,,,,Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method,Other,21098647.0,
1869,1211297,1,1,,103164951,4946,Unspecified,,,,,Drug recovery in plasma (unknown origin),Other,21098647.0,
1870,1211298,1,1,,103164951,4946,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21098647.0,
1871,1211791,1,1,,103164951,4946,Unspecified,,,,,Fraction unbound in human hepatocytes,Other,21998403.0,
1872,1211792,1,1,,103164951,4946,Unspecified,,,,,Hepatic clearance in human,Other,21998403.0,
1873,1211793,1,1,,103164951,4946,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,21998403.0,
1874,1211794,1,2,,103164951,4946,Unspecified,,,,,Fraction unbound in blood (not specified),Other,21998403.0,
1875,1211795,1,1,,103164951,4946,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21998403.0,
1876,1211797,1,1,,103164951,4946,Unspecified,,,,,Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method,Other,21998403.0,
1877,1211798,1,1,,103164951,4946,Unspecified,,,,,Intrinsic clearance in human using well stirred liver model by LC-MS/MS method,Other,21998403.0,
1878,1212311,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM preincubated with chloroquine followed by compound treatment measured after 5 mins by LC-MS analysis,Other,23378628.0,
1879,1212314,1,1,,103164951,4946,Unspecified,,,92.0,IC50,Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins,Confirmatory,23378628.0,
1880,1212316,1,1,,103164951,4946,Unspecified,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning measured per 10'6 cells at 1 uM after 5 mins by LC-MS analysis,Other,23378628.0,
1881,1212317,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning measured per 10'6 cells at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride,Other,23378628.0,
1882,1212318,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM up to 10 mins by LC-MS analysis,Other,23378628.0,
1883,1212319,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM measured at 10 mins by LC-MS analysis in presence of ammonium chloride,Other,23378628.0,
1884,1212320,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM co-incubated with ammonium chloride for 5 mins by LC-MS analysis,Other,23378628.0,
1885,1212321,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM co-incubated with chloroquine for 5 mins by LC-MS analysis,Other,23378628.0,
1886,1212322,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM preincubated with ammonium chloride followed by compound treatment measured after 5 mins by LC-MS analysis,Other,23378628.0,
1887,1212323,1,1,,103164951,4946,Active,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM preincubated with ammonium chloride for 5 mins followed by media washout and compound treatment measured after 5 mins by LC-MS analysis,Other,23378628.0,
1888,1212324,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM preincubated with chloroquine for 5 mins followed by media washout and compound treatment measured after 5 mins by LC-MS analysis,Other,23378628.0,
1889,1212325,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride,Other,23378628.0,
1890,1212326,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of nigericin and monensin,Other,23378628.0,
1891,1212327,1,1,,103164951,4946,Inactive,,,,,"Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of ammonium chloride, nigericin and monensin",Other,23378628.0,
1892,1212328,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of astemizole,Other,23378628.0,
1893,1212329,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of dextromethorphan,Other,23378628.0,
1894,1212330,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of chloroquine,Other,23378628.0,
1895,1212331,1,1,,103164951,4946,Inactive,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of imipramine,Other,23378628.0,
1896,1212333,1,1,,103164951,4946,Active,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of diclofenac,Other,23378628.0,
1897,1212334,1,1,,103164951,4946,Active,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of rifampin,Other,23378628.0,
1898,1212335,1,1,,103164951,4946,Active,,,,,Drug uptake in lysosomes of human Fa2N-4 cells assessed as cellular partitioning at 1 uM after 5 mins by LC-MS analysis in presence of atorvastatin,Other,23378628.0,
1899,1212341,1,1,,103164951,4946,Unspecified,,,,,Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay,Other,23378628.0,
1900,1215121,1,2,,103164951,4946,Unspecified,,,,,Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method,Other,21071520.0,
1901,1215122,1,1,,103164951,4946,Unspecified,,,,,Fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay,Other,21071520.0,
1902,1215125,1,1,,103164951,4946,Unspecified,,,,,Fraction unbound in solid supported porcine brain membrane vesicles at 5 uM using four compound cocktail after 5 hrs by TRANSIL assay,Other,21071520.0,
1903,1215126,1,2,,103164951,4946,Unspecified,,,,,Ratio of fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay,Other,21071520.0,
1904,1215128,1,1,,103164951,4946,Unspecified,,,,,"Ratio, ratio of fraction unbound in solid supported porcine brain membrane vesicles at 5 uM dosed as discrete compounds after 5 hrs by TRANSIL assay to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM using four compound cocktail after 5 hrs by TRANSIL assay",Other,21071520.0,
1905,1215671,1,2,,103164951,4946,Unspecified,215273968.0,316.0,,,Drug metabolism in pooled human hepatocytes assessed as aldehyde oxidase-mediated drug metabolism at 10 uM up to 120 mins by HPLC analysis in presence of 25 uM of hydralazine,Other,22522748.0,
1906,1215672,1,2,,103164951,4946,Unspecified,215273968.0,316.0,,,Drug metabolism in pooled human hepatocytes assessed as aldehyde oxidase-mediated drug metabolism at 10 uM up to 120 mins by HPLC analysis in presence of 50 uM of hydralazine,Other,22522748.0,
1907,1217704,1,2,,103164951,4946,Unspecified,117144.0,1544.0,,,Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1908,1217705,1,2,,103164951,4946,Unspecified,117205.0,1555.0,,,Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1909,1217706,1,2,,103164951,4946,Unspecified,6686268.0,1559.0,,,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1910,1217707,1,2,,103164951,4946,Unspecified,60416369.0,1557.0,,,Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system,Other,21467212.0,
1911,1217708,1,2,,103164951,4946,Unspecified,84028191.0,1565.0,,,Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1912,1217709,1,2,,103164951,4946,Unspecified,116241312.0,1576.0,,,Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1913,1217710,1,2,,103164951,4946,Unspecified,,,,,Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting,Other,21467212.0,
1914,1217711,1,2,,103164951,4946,Unspecified,,,,,Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
1915,1217712,1,2,,103164951,4946,Unspecified,117225.0,1558.0,,,Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system,Other,21467212.0,
1916,1217727,1,2,,103164951,4946,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay,Other,21467212.0,
1917,1217728,1,1,,103164951,4946,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay,Other,21467212.0,
1918,1217729,1,1,,103164951,4946,Unspecified,,,,,Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation,Other,21467212.0,
1919,1220969,1,2,,103164951,4946,Unspecified,,,,,Drug distribution in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed as equilibrium amount ratio charactering fast binding process at 8 mM after 10 mins,Other,21245286.0,
1920,1220971,1,2,,103164951,4946,Unspecified,,,,,Drug distribution in healthy Wistar rat perfused liver assessed as equilibrium amount ratio charactering slow binding process at 8 mM after 10 mins,Other,21245286.0,
1921,1220975,1,2,,103164951,4946,Unspecified,,,,,Drug distribution in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed as equilibrium amount ratio charactering slow binding process at 8 mM after 10 mins,Other,21245286.0,
1922,1220979,1,1,,103164951,4946,Unspecified,,,,,"Octanol-water apparent partition coefficient, log Papp of the compound at pH 7.4",Other,21245286.0,
1923,1220980,1,1,,103164951,4946,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,21245286.0,
1924,1220981,1,1,,103164951,4946,Unspecified,,,,,Extraction ratio of the compound in healthy Wistar rat perfused liver at 8 mM after 10 mins,Other,21245286.0,
1925,1220985,1,1,,103164951,4946,Unspecified,,,,,Extraction ratio of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 8 mM after 10 mins,Other,21245286.0,
1926,1220989,1,1,,103164951,4946,Unspecified,,,,,Mean transit time of the compound in healthy Wistar rat perfused liver at 8 mM after 10 mins,Other,21245286.0,
1927,1220993,1,1,,103164951,4946,Unspecified,,,,,Mean transit time of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 8 mM after 10 mins,Other,21245286.0,
1928,1220997,1,1,,103164951,4946,Unspecified,,,,,Permeability surface area product in healthy Wistar rat perfused liver assessed per gm of liver at 8 mM after 10 mins,Other,21245286.0,
1929,1221001,1,1,,103164951,4946,Unspecified,,,,,Permeability surface area product in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed per gm of liver at 8 mM after 10 mins,Other,21245286.0,
1930,1221005,1,2,,103164951,4946,Unspecified,,,,,Apparent distribution ratio of the compound in healthy Wistar rat perfused liver at 8 mM after 10 mins,Other,21245286.0,
1931,1221009,1,2,,103164951,4946,Unspecified,,,,,Apparent distribution ratio of the compound in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat at 8 mM after 10 mins,Other,21245286.0,
1932,1221013,1,1,,103164951,4946,Unspecified,,,,,Intrinsic elimination clearance in healthy Wistar rat perfused liver assessed per gm of liver at 8 mM after 10 mins,Other,21245286.0,
1933,1221017,1,1,,103164951,4946,Unspecified,,,,,Intrinsic elimination clearance in perfused liver of high-fat emulsion-induced nonalcoholic steatohepatitis Wistar rat assessed per gm of liver at 8 mM after 10 mins,Other,21245286.0,
1934,1221021,1,2,,103164951,4946,Unspecified,,,,,Drug distribution in healthy Wistar rat perfused liver assessed as equilibrium amount ratio charactering fast binding process at 8 mM after 10 mins,Other,21245286.0,
1935,1222766,1,1,,103164951,4946,Unspecified,,,,,Unbound hepatobiliary clearance in human,Other,23454828.0,
1936,1222767,1,1,,103164951,4946,Unspecified,,,,,Unbound renal clearance in human,Other,23454828.0,
1937,1222768,1,1,,103164951,4946,Unspecified,,,,,Systemic clearance in human,Other,23454828.0,
1938,1222769,1,1,,103164951,4946,Unspecified,,,,,Fraction unbound in human,Other,23454828.0,
1939,1222793,1,1,,103164951,4946,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,23454828.0,
1940,1223488,1,1,,103164951,4946,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4",Other,22096083.0,
1941,1223490,1,1,,103164951,4946,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells,Other,22096083.0,
1942,1224859,2,1,,90341556,4946,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1943,1224863,1,1,,176484460,4946,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1944,1224863,1,1,,316919036,4946,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1945,1224905,2,1,,92309237,4946,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1946,1224905,2,1,,92309237,4946,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1947,1224905,2,1,,252565737,4946,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1948,1224905,2,1,,252565737,4946,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1949,1226790,1,1,,103164951,4946,Unspecified,,,,,Permeability of the compound assessed as drug transmittance level at 10 uM after 5 hrs by LC-MS detection based PAMPA method,Other,25950816.0,
1950,1226792,1,1,,103164951,4946,Unspecified,,,,,Permeability of the compound at 10 uM after 5 hrs by LC-MS detection based PAMPA method,Other,25950816.0,
1951,1226796,1,1,,103164951,4946,Unspecified,,,,,Apparent permeability from apical to basolateral side in low-efflux MDCK cells expressing low levels of endogenous P-glycoprotein at 2 mM incubated for 2 hrs by LC-MS/MS method,Other,25950816.0,
1952,1230989,1,1,,103164951,4946,Unspecified,,,,,Permeability of the compound at pH 7.4 by PAMPA,Other,26111355.0,
1953,1237774,1,1,,103164951,4946,Unspecified,,,,,Intrinsic clearance in human liver microsomes assessed per mg of protein preincubated for 10 mins followed by NADP/Glc6P/G6P-DH addition by LC-MS/MS analysis,Other,26132075.0,
1954,1237776,1,1,,103164951,4946,Unspecified,,,,,Intrinsic clearance in mouse liver microsomes assessed per mg of protein preincubated for 10 mins followed by NADP/Glc6P/G6P-DH addition by LC-MS/MS analysis,Other,26132075.0,
1955,1242929,1,1,,103164951,4946,Unspecified,,,,,Effective permeability by PAMPA method,Other,26231155.0,
1956,1245599,1,1,,103164951,4946,Unspecified,,,,,Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Caco2 cells after 2 hrs,Other,26344593.0,
1957,1254934,1,1,,103164951,4946,Unspecified,,,,,Efflux ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells after 2 hrs by LC-MS/MS method,Other,26363868.0,
1958,1256760,1,1,,103164951,4946,Unspecified,,,,,Permeability of the compound at 10 mM after 4 hrs by PAMPA,Other,26491978.0,
1959,1259325,1,2,,336954445,4946,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1960,1259370,2,2,,124659742,4946,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1961,1259370,2,2,,124659742,4946,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1962,1259370,2,2,,124659742,4946,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1963,1259389,1,1,,124659742,4946,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
1964,1259407,1,1,,363901032,4946,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1965,1259409,1,1,,363901032,4946,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
1966,1259416,1,2,,340080504,4946,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1967,1259416,1,2,,375177885,4946,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1968,1259421,1,1,,340080504,4946,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1969,1259421,1,1,,375177885,4946,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1970,1259423,1,2,,354784265,4946,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1971,1259423,1,2,,354841038,4946,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1972,1259423,1,2,,354925532,4946,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1973,1259423,1,2,,354968129,4946,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1974,1259423,1,2,,354968403,4946,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1975,1259423,1,2,,355013157,4946,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
